https://rjrindex.com/articles/prospective-cohort-study-of-palbociclib-in-hrher2-metastatic-breast-cancer-in-japan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-epacadostat-incb024360-added-to-preoperative-chemoradiation-in-patients-with-loc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-cardiology-referral-in-breast-cancer-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mayhem-under-the-microscope-t-cell-cytotoxicity-and-serial-killers-captured-in-situ 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-coronary-artery-calcification-in-breast-cancer-survivors-with-age-matched-controls-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/novel-dynamic-circulating-biomarkers-for-predicting-therapeutic-efficacy-of-prag-regimen-in-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relationships-among-polyunsaturated-fatty-acid-profiles-immune-landscapes-and-immunotherapy-progno 2026-08-24 monthly 0.7 https://rjrindex.com/articles/identification-of-tissue-resident-adaptive-nk-cells-and-their-association-with-reduced-mortality-acr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-factors-and-prognostic-outcomes-of-hyperthyroidism-induced-by-immune-checkpoint-inhibitor-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predictors-of-septic-shock-among-bcrabl-positive-chronic-myeloid-leukemia-patients-admitted-for-sep 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sup177sup-lu-psma-617-consolidation-therapy-post-docetaxel-in-patients-with-de-novo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/procedure-for-pooling-clinical-outcome-data-from-drup-like-clinical-trials-using-the-omop-model 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-feasibility-study-on-delayed-selective-sentinel-node-biopsy-for-patients-undergoing-mast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1-study-of-gotistobart-bnt316onc-392-in-combination-with-lutetium-lu-177-vipivotide-tetraxe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-implications-of-her3-overexpression-in-a-diverse-patient-cohort-with-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/integration-of-a-virtual-personalized-medicine-review-board-integration-into-a-major-community-oncol 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-outcomes-of-dynamic-sentinel-lymph-node-biopsy-in-clinically-node-negative-penile-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decoding-disparities-a-seer-analysis-of-treatment-patterns-and-timelines-for-orbital-embryonal-rhab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/exploring-the-weekend-effect-and-other-predictors-of-mortality-in-tumor-lysis-syndrome-among-hospita 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hipec-combined-with-camrelizumab-paclitaxel-and-s-1-for-conversion-therapy-in-patients-with-advance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathogenic-germline-variants-in-breast-cancer-patients-associated-with-different-her2-expression-lev 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-trial-of-tu2218-tgfv-ri-and-vegf-r2-dual-inhibitor-in-combination-with-pembrolizumab-in-pa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/smart-cell-combined-with-pd-1-blockade-and-sox-as-first-line-treatment-for-patients-with-advanced-ga 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-bayesian-population-based-framework-for-detecting-hyperprogressive-disease-on-cancer-immunotherapi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pain-in-cancer-survivors-in-the-us-after-federal-and-state-opioid-prescribing-guidelines-and-laws 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mutations-in-homologous-recombination-dna-damage-repair-genes-and-treatment-outcomes-to-immune-check 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mutation-profiling-of-appendiceal-cancer-distinguishing-tumor-grades-comprehensive-mutation-landsc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multimodal-ai-using-host-tumor-and-ghost-biomarker-for-predicting-immunotherapy-efficacy-in-nsclc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/late-toxicities-lt-in-patients-affected-by-locally-advanced-la-oropharyngeal-carcinoma-opc-tre 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-mutant-stk11-keap1-and-kras-on-firstline-chemoimmunotherapy-survival-outcomes-in-metasta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-12-study-of-vusolimogene-oderparepvec-rp1-in-primary-melanoma-mel-to-reduce-the-risk-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ocular-toxicities-observed-in-polypeptide-vaccine-trials-for-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-dna-dynamics-and-pathologic-response-to-neoadjuvant-immunotherapy-in-resectable-st 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artificial-intelligence-for-immunotherapy-response-assessment-in-lung-cancer-using-pet-ct-reports 2026-08-24 monthly 0.7 https://rjrindex.com/articles/major-pathological-response-to-neoadjuvant-immune-related-therapy-and-influence-on-long-term-surviva 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tracking-circulating-tumor-dna-through-liquid-biopsy-after-radiotherapy-for-dynamic-risk-monitoring 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-reported-outcomes-pros-in-the-c-post-trial-of-adjuvant-cemiplimab-cemi-vs-placebo-pbo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lymph-node-excision-lnex-for-patients-with-stage-iii-melanoma-with-one-clinically-positive-node-e 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combining-abemaciclib-temozolomide-and-radiation-in-dipg-pdox-models-insights-from-single-cell-rn 2026-08-24 monthly 0.7 https://rjrindex.com/articles/from-retrospective-analysis-to-real-world-impact-mismatch-repair-deficiency-detection-in-gliomas-by 2026-08-24 monthly 0.7 https://rjrindex.com/articles/21-years-of-tonsillar-cancer-mortality-trends-disparities-and-public-health-challenges 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-brain-protein-i3-bri3-to-predict-disease-fate-in-glioblastoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/aurora-a-single-arm-multicentre-phase-ii-clinical-trial-of-atezolizumab-immunotherapy-for-advance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-trial-of-perioperative-oral-itraconazole-for-the-management-of-low-risk-basal-cell-carcin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/next-generation-sequencing-in-patients-with-liposarcoma-and-rhabdomyosarcoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reflexed-molecular-testing-to-identify-patients-with-biomarkers-associated-with-tumor-agnostic-fda-d 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combined-preoperative-segmental-hepatic-arteries-embolization-with-hepatic-artery-resection-in-radic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/design-of-a-phase-1-trial-of-ilisteriai-imonocytogenesi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ultra-sensitive-detection-of-hepatocellular-carcinoma-hcc-with-methylation-signal-enrichment-of-ct 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transcriptomic-landscape-of-kaposi-sarcoma-insights-into-therapeutic-targeting-of-kshv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tt125-802-a-highly-selective-well-tolerated-bromodomain-inhibitor-of-cbpp300-with-anti-tumor-acti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-retrospective-analysis-of-metaplastic-triple-negative-breast-cancer-response-to-sacituzumab-govite 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-optimized-hlh-inflammatory-index-a-novel-prognostic-tool-for-newly-diagnosed-patients-with-diff 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combination-of-zanubrutinib-zanu-venetoclax-ven-for-treatment-naive-tn-cllsll-results-in-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-3-randomized-study-of-adjuvant-sacituzumab-tirumotecan-plus-pembrolizumab-vs-treatment-of-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-predictors-and-prognostic-significance-of-pathologic-disease-upstaging-at-radical-cystectom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mct1-mediated-histone-lactylation-modulates-lung-cancer-cell-sensitivity-to-t-cell-mediated-killing 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-residual-disease-mrd-in-solid-tumors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-utility-of-ctdna-before-and-after-trimodality-therapy-tmt-for-muscle-invasive-bladder-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/understanding-tobacco-use-and-cessation-challenges-amongst-patients-with-lung-cancer-elucidating-de 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-creaformo-004-study-a-phase-ii-study-of-hr070803-plus-5-fluorouracilleucovorin-and-bevacizumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-a-biology-based-novel-therapeutic-agent-targeting-the-lin28 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-kras-mutation-status-on-outcomes-in-peritoneal-metastatic-mucinous-adenocarcinoma-of-the-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-process-evaluation-trial-of-a-telehealth-service-intervention-to-support-uptake-of-breast-cancer-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-study-of-anti-pd-1-combined-with-regorafenib-and-raltitrexed-as-third-line-therapy-in-col 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dynamic-hematological-indicators-as-predictors-of-cdk46-inhibitors-efficacy-in-hr-positive-her2-ne 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genetic-epidemiology-of-colorectal-cancer-in-morocco-a-systematic-review-and-meta-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-checkpoint-blockade-in-locally-advanced-rectal-cancer-with-deficient-mismatch-repair-dmmr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sacituzumab-govitecan-initial-dose-reduction-in-polish-patients-with-metastatic-triple-negative-brea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/differences-in-supportive-care-service-utilization-among-long-term-metastatic-breast-cancer-survivor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-kaposis-sarcoma-in-a-cohort-of-hiv-negative-men-who-have-sex-with-men-an-obse 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-according-to-timing-of-immune-checkpoint-inhibitors-administration-in-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dissecting-racial-socioeconomic-and-treatment-disparities-in-peripheral-t-cell-lymphoma-a-compreh 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-determinants-and-outcomes-of-hypothyroidism-in-immune-checkpoint-inhibitor-ici-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-activity-of-immune-checkpoint-blockade-in-advanced-perivascular-epithelioid-cell-neoplasms 2026-08-24 monthly 0.7 https://rjrindex.com/articles/brexucabtagene-autoleucel-brexu-cel-as-consolidation-treatment-in-adults-with-b-cell-acute-lymphob 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-onset-eo-cancer-trends-in-brazil-a-comprehensive-analysis-of-hospital-based-cancer-registry 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dreamseq-a-phase-iii-trial-of-treatment-sequences-in-brafv600-mutant-m-metastatic-melanoma-mm-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-first-in-human-phase-iib-study-of-atg-037-monotherapy-and-combination-therapy-with-pembrolizumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ciltacabtagene-autoleucel-cilta-cel-vs-standard-of-care-soc-in-patients-pts-with-relapsedrefr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ibi354-an-anti-her2-antibody-drug-conjugate-in-patients-with-locally-advanced-unresectable-or-meta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tebentafusp-in-metastatic-uveal-melanoma-patients-results-of-the-italian-expanded-access-program 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dendritic-cell-based-vaccines-ksd-101-against-ebv-associated-lymphoproliferative-diseases-results 2026-08-24 monthly 0.7 https://rjrindex.com/articles/percutaneous-hepatic-perfusion-php-with-melphalan-for-treatment-of-liver-metastases-from-uveal-mel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-zanzalintinib-xl-092-in-combination-with-durvalumab-and-tremelimumab-in-unresect 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-efficacy-and-safety-of-ivosidenib-in-us-veterans-with-idh1-mutated-cholangiocarcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-in-patients-with-hrher2-advanced-or-metastatic-breast-cancer-treated-with-a-cycl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-indocyanine-green-icg-and-handheld-fluorescence-imager-in-the-management-of-early-st 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-prostate-cancer-risk-groups-by-psma-pet-promise-ppp2-results-from-an-international-multi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/everest-1-safety-and-efficacy-data-of-a2b530-a-logic-gated-tmod-chimeric-antigen-receptor-t-cell 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-azd0486-a-cd19xcd3-t-cell-engager-in-relapsed-or-refractory-diffuse-large-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combined-treatment-of-durvalumab-bevacizumab-and-tremelimumab-in-subjects-with-hepatocellular-carci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-monitoring-of-prostate-specific-membrane-antigen-positive-biochemically-recurrent-prosta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-a-phase-1-study-of-vosilasarm-ep0062-a-first-in-class-oral-selective-androgen-receptor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/defendor-special-effect-of-primary-prophylaxis-with-empegfilgrastim-on-pcr-rate-after-neoadjuvant-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/zanzalintinib-zanza-nivolumab-nivo-relatlimab-rela-in-patients-pts-with-advanced-solid-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artificial-intelligence-powered-spatial-analysis-of-tumor-infiltrating-lymphocytes-and-tertiary-lymp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-pembrolizumab-in-combination-with-dabrafenib-and-trametinib-dtp-for-ibra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-studies-industry-neglects-characteristics-of-cancer-clinical-trials-conducted-by-federal-versus 2026-08-24 monthly 0.7 https://rjrindex.com/articles/familial-lung-cancer-a-thirteen-year-prospective-analysis-of-participants-with-germline-egfr-t790m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-immunotherapy-in-combination-with-chemotherapy-in-resectable-locally-advanced-head-and-n-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cohort-builder-in-tempus-lens-querying-a-large-oncology-database-with-generative-ai 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multiomic-analysis-of-cutaneous-squamous-cell-carcinoma-cscc-and-association-with-response-to-anti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/from-text-to-insight-methods-for-validation-of-nlp-extracted-real-world-oncology-data-using-a-human 2026-08-24 monthly 0.7 https://rjrindex.com/articles/substudy-f-of-the-canadian-cancer-trials-group-cctg-ind234-pc-bets-prostate-cancer-biomarker-en 2026-08-24 monthly 0.7 https://rjrindex.com/articles/novel-dendritic-cells-targeting-mrna-lnp-vaccine-with-potent-anti-tumor-activity-in-vivo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/total-neoadjuvant-therapy-with-induction-immunochemotherapy-and-chemoradiotherapy-followed-by-surger 2026-08-24 monthly 0.7 https://rjrindex.com/articles/envafolimab-plus-docetaxel-in-combination-with-or-without-trilaciclib-versus-docetaxel-in-pretreated 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-heterogeneity-between-primary-and-paired-recurrent-breast-cancer-and-its-potential-molecular-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artificial-intelligence-powered-spatial-analysis-of-tumor-microenvironment-in-non-small-cell-lung-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-prompt-versus-deferred-sup177sup-lu-psma-617-initi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/toxicity-profile-of-enfortumab-vedotin-with-or-without-pembrolizumab-in-patients-with-metastatic-uro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/accuracy-of-artificial-intelligence-models-integrating-machine-learning-and-deep-learning-in-detecti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-survival-between-liver-only-metastasis-and-other-metastatic-sites-in-patients-with-de 2026-08-24 monthly 0.7 https://rjrindex.com/articles/small-nucleolar-rnas-snornas-expression-and-effects-on-patient-pt-outcomes-in-metastatic-colorec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predicting-pathologic-complete-response-pcr-from-clinicopathologic-variables-and-her2dx-genomic-te 2026-08-24 monthly 0.7 https://rjrindex.com/articles/final-analysis-of-fixed-duration-ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cllsmall 2026-08-24 monthly 0.7 https://rjrindex.com/articles/stereotactic-radiation-versus-hippocampal-avoidance-whole-brain-radiation-in-patients-with-5-20-brai 2026-08-24 monthly 0.7 https://rjrindex.com/articles/letetresgene-autoleucel-in-advancedmetastatic-myxoidround-cell-liposarcoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/letetresgene-autoleucel-a-milestone-in-treatment-of-myxoidround-cell-liposarcoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tamales 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-randomized-comparison-of-magnetic-resonance-imaging-versus-transurethral-resection-for-stag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/entering-the-era-of-multidimensional-prognostication-for-personalized-risk-assessment-in-stage-iii-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-first-in-human-study-of-for46-fg-3246-an-immune-modulating-antibody-drug-conjugate-targe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trend-and-provider-and-organizational-level-factors-associated-with-early-palliative-care-billing-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/high-dose-methotrexate-in-children-and-young-adults-with-all-and-lymphoblastic-lymphoma-results-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/challenges-in-assessing-response-in-clinical-trials-for-neurofibromatosis-type-1-plexiform-neurofibr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-models-from-transcriptomic-signatures-of-the-tumor-microenvironment-and-cell-cycle-in-sta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-open-label-phase-iii-study-of-tilsotolimod-in-combination-with-ipilimumab-versus-ipilim 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-treatment-intensification-based-on-residual-disease-in-elderly-patients-with-aml 2026-08-24 monthly 0.7 https://rjrindex.com/articles/complementing-anticancer-therapy-antibody-drug-conjugates-targeting-cd46-as-prostate-cancer-treatme 2026-08-24 monthly 0.7 https://rjrindex.com/articles/selpercatinib-in-ireti-fusion-positive-non-small-cell-lung-cancer-fina 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-intensification-based-on-residual-disease-in-elderly-patients-with-aml 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-challenges-in-assessing-response-in-clinical-trials-for-neurofibromatosis-type-1-plexiform 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risks-of-organ-preservation-in-rectal-cancer-beyond-distant-metastases-ultimate-local-failure-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-risks-of-organ-preservation-in-rectal-cancer-beyond-distant-metastases-ultimate-local-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/distant-metastases-with-nonoperative-management-in-rectal-cancer-challenges-in-defining-risk 2026-08-24 monthly 0.7 https://rjrindex.com/articles/organ-preservation-in-rectal-cancer-fear-of-risks-versus-the-risks-of-fear 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pertuzumab-retreatment-for-human-epidermal-growth-factor-receptor-2-positive-locally-advancedmetast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-pembrolizumab-in-combination-with-bevacizumab-for-untreated-melanoma-brain-metasta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-pertuzumab-retreatment-for-human-epidermal-growth-factor-receptor-2-positive-locally-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/they-not-like-us-evaluating-the-diverse-strategies-in-locally-advanced-rectal-cancer-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-checkpoint-combos-in-metastatic-castration-resistant-prostate-cancer-where-are-we-going-wha 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frequency-and-clinical-significance-of-clonal-and-subclonal-driver-mutations-in-high-risk-neuroblast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pembrolizumab-plus-docetaxel-versus-docetaxel-for-previously-treated-metastatic-castration-resistant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sentinel-lymph-node-biopsy-in-early-stage-breast-cancer-asco-guideline-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/allogeneic-chimeric-antigen-receptor-t-cell-products-cemacabtagene-ansegedleucelallo-501-in-relapse 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cosmic-021-phase-ib-study-of-cabozantinib-plus-atezolizumab-results-from-the-locally-advanced-or-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/where-is-the-future-of-adjuvant-therapy-for-hepatocellular-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risks-of-organ-preservation-in-rectal-cancer-data-from-two-international-registries-on-rectal-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-behavior-of-breast-cancer-in-young-ibrcai-carriers-and-prediag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enfortumab-vedotin-a-promising-therapy-for-head-and-neck-cancer-with-potential-links-to-human-papil 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combined-analyses-of-circulating-tumor-dna-and-immunoscore-in-patients-with-stage-iii-colon-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-standard-of-care-idecabtagene-vicleucel-and-ciltacabtagene-autoleucel-in-relapsedrefr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/three-year-overall-survival-with-nivolumab-plus-relatlimab-in-advanced-melanoma-from-relativity-047 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-osimertinib-plus-antiangiogenic-agents-a-promising-new-paradigm-with-uncertain-results 2026-08-24 monthly 0.7 https://rjrindex.com/articles/making-progress-along-the-challenging-road-of-drug-development-for-patients-with-iegfr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/fulvestrant-versus-anastrozole-in-endocrine-therapy-naive-women-with-hormone-receptor-positive-advan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-health-related-quality-of-life-in-transplant-ineligible-patients-with-newly-diagnosed-multi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-first-hero 2026-08-24 monthly 0.7 https://rjrindex.com/articles/breast-colorectal-and-pancreatic-cancer-mortality-with-pathogenic-variants-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-neoadjuvant-durvalumab-plus-gemcitabinecisplatin-or-carboplatin-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/osimertinib-plus-antiangiogenic-agents-a-promising-new-paradigm-with-uncertain-results 2026-08-24 monthly 0.7 https://rjrindex.com/articles/geospatial-genomics-operationalizing-multilevel-conceptual-frameworks-of-cancer-health-outcomes-to 2026-08-24 monthly 0.7 https://rjrindex.com/articles/management-of-patients-with-iegfri-exon-20-mutant-advanced-non-small-ce 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-enfortumab-vedotin-a-promising-therapy-for-head-and-neck-cancer-with-potential-links-to-h 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-naldemedine-for-opioid-induced-constipation-in-patients-with-cancer-a-multicenter-double 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-mobocertinib-versus-platinum-based-chemotherapy-in-patients-with-iegfri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a-treatment-naive-chronic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/fertility-preservation-in-people-with-cancer-asco-guideline-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-glofitamab-for-the-treatment-of-relapsedrefractory-mantle-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/surrogate-end-points-for-overall-survival-in-neoadjuvant-randomized-clinical-trials-for-early-breast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/machine-learning-to-predict-mortality-in-older-patients-with-cancer-development-and-external-valida 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glofitamab-for-the-treatment-of-relapsedrefractory-mantle-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/baseline-liquid-biopsy-in-relation-to-tissue-based-parameters-in-metastatic-colorectal-cancer-resul 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-nivolumab-plus-ipilimumab-versus-chemotherapy-in-resectable-lung-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/i-hope-so-too 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rethinking-the-path-to-bladder-cancer-staging-can-magnetic-resonance-imaging-speed-up-time-to-recei 2026-08-24 monthly 0.7 https://rjrindex.com/articles/missed-opportunity-for-sotorasib-dose-optimization 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-paclitaxel-ifosfamide-and-cisplatin-as-initial-salvage-chemotherapy-for-germ-cell-tumors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/data-models-and-visuals-how-data-science-methods-can-augment-geriatric-oncology-research 2026-08-24 monthly 0.7 https://rjrindex.com/articles/olaparib-as-treatment-versus-nonplatinum-chemotherapy-in-patients-with-platinum-sensitive-relapsed-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/postoperative-radiotherapy-cetuximab-for-intermediate-risk-head-and-neck-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/automatic-for-the-people-what-has-machine-learning-analysis-of-positron-emission-tomography-left-fo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-randomized-comparison-of-intensified-six-drug-versus-standard-three-drug-chemotherapy-for-h 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-comparison-of-standard-of-care-idecabtagene-vicleucel-and-ciltacabtagene-autoleucel-in-rela 2026-08-24 monthly 0.7 https://rjrindex.com/articles/minimal-residual-disease-based-end-point-for-accelerated-assessment-of-clinical-trials-in-multiple-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trastuzumab-pertuzumab-plus-eribulin-or-taxane-as-first-line-chemotherapy-for-human-epidermal-growth 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-first-line-nivolumab-plus-relatlimab-versus-nivolumab-plus-ipilimumab-in-advanced-melanoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trastuzumab-plus-pertuzumab-versus-cetuximab-plus-irinotecan-in-patients-with-irasbra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/botensilimab-fc-enhanced-anti-cytotoxic-lymphocyte-association-protein-4-antibody-plus-balstilimab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transoral-robotic-surgery-in-the-multidisciplinary-care-of-patients-with-oropharyngeal-squamous-cell 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lessons-from-taxanes-versus-eribulin-for-first-line-metastatic-human-epidermal-growth-factor-recepto 2026-08-24 monthly 0.7 https://rjrindex.com/articles/supervised-exercise-for-patients-with-metastatic-breast-cancer-a-cost-utility-analysis-alongside-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/accelerating-myeloma-drug-development-will-minimal-residual-disease-replace-progression-free-surviv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-ne 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-automatic-for-the-people-what-has-machine-learning-analysis-of-positron-emission-tomograp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/her2-selective-tyrosine-kinase-inhibitor-zongertinib-bi-1810631-in-patients-with-advancedmetast 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-inferior-control-arms-in-prostate-cancer-trials-the-aranote-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inferior-control-arms-in-prostate-cancer-trials-the-aranote-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metronomic-capecitabine-plus-aromatase-inhibitor-as-initial-therapy-in-patients-with-hormone-recepto 2026-08-24 monthly 0.7 https://rjrindex.com/articles/timely-reporting-of-patient-reported-outcomes-in-cancer-clinical-trials-an-ethical-imperative 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-living-guideline-vers-3 2026-08-24 monthly 0.7 https://rjrindex.com/articles/larotrectinib-for-newly-diagnosed-infantile-fibrosarcoma-and-other-pediatric-intrki 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparative-analysis-of-intracranial-response-assessment-criteria-in-patients-with-melanoma-brain-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapy-for-stage-iv-non-small-cell-lung-cancer-without-driver-alterations-asco-living-guideline-v-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-denileukin-diftitox-cxdl-an-improved-purity-formulation-of-denileukin-diftit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adjuvant-dose-dense-chemotherapy-in-hormone-receptor-positive-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concerns-on-potential-risk-of-roxadustat-in-promoting-tumor-progression-double-edged-sword-of-hypox 2026-08-24 monthly 0.7 https://rjrindex.com/articles/aiming-targeted-drug-development-at-rare-pediatric-malignancies 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-concerns-on-potential-risk-of-roxadustat-in-promoting-tumor-progression-double-edged-swor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-elective-discontinuation-of-larotrectinib-in-pediatric-patients-with-trk-fusion-sarcomas-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/melanoma-among-adult-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-stud 2026-08-24 monthly 0.7 https://rjrindex.com/articles/datopotamab-deruxtecan-in-advanced-or-metastatic-non-small-cell-lung-cancer-with-actionable-genomic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/elective-discontinuation-of-larotrectinib-in-pediatric-patients-with-trk-fusion-sarcomas-and-related 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adjuvant-chemotherapy-on-resected-intraductal-papillary-mucinous-neoplasm-derived-pancreatic-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-follow-up-and-overall-survival-in-nrg258-a-randomized-phase-iii-trial-of-chemoradiation-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/radiofrequency-ablation-versus-stereotactic-body-radiotherapy-for-recurrent-small-hepatocellular-car 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nivolumab-with-or-without-ipilimumab-in-patients-with-recurrent-or-metastatic-merkel-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/de-escalation-strategies-with-immune-checkpoint-blockers-in-non-small-cell-lung-cancer-do-we-alread 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/brentuximab-vedotin-combination-for-relapsed-diffuse-large-b-cell-lymphoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/what-is-the-optimal-locoregional-approach-for-recurrent-hepatocellular-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-phase-iii-trial-of-mixed-formulation-of-fosrolapitant-and-palonosetron-hr20013-in-prev 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-risk-enabled-therapy-after-neoadjuvant-chemotherapy-for-muscle-invasive-bladder-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/expanding-the-horizon-of-mronj-research-in-breast-cancer-bone-metastasis-treatments 2026-08-24 monthly 0.7 https://rjrindex.com/articles/abemaciclib-plus-fulvestrant-in-advanced-breast-cancer-after-progression-on-cdk46-inhibition-resul 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-adjuvant-chemotherapy-on-resected-intraductal-papillary-mucinous-neoplasm-derived-pancreat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-and-surgical-management-of-pediatric-cutaneous-melanoma-and-atypical-spitz-and-non-spitz 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-lenvatinib-plus-pembrolizumab-versus-chemotherapy-for-advanced-endometrial-cancer-a-rand 2026-08-24 monthly 0.7 https://rjrindex.com/articles/improved-patient-reported-outcomes-with-post-transplant-cyclophosphamide-a-quality-of-life-evaluati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/should-total-neoadjuvant-therapy-be-the-first-line-treatment-for-patients-with-locally-advanced-rect 2026-08-24 monthly 0.7 https://rjrindex.com/articles/oxaliplatin-based-versus-alkylating-agent-in-neuroendocrine-tumors-according-to-the-o-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/accurate-determinants-of-outcome-in-all 2026-08-24 monthly 0.7 https://rjrindex.com/articles/using-cure-models-for-trial-analysis-and-design 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-should-total-neoadjuvant-therapy-be-the-first-line-treatment-for-patients-with-locally-adv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-fulvestrant-versus-anastrozole-in-endocrine-therapy-naive-women-with-hormone-receptor-posit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-the-rsclinn-tool-to-predict-prognosis-and-chemotherapy-benefit-for-ho 2026-08-24 monthly 0.7 https://rjrindex.com/articles/combination-immunotherapy-with-nivolumab-plus-ipilimumab-in-melanoma-of-unknown-primary 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-nivolumab-plus-doxorubicin-vinblastine-dacarbazine-as-frontline-therapy-in-older 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-busulfan-plus-fludarabine-compared-with-busulfan-plus-cyclophosphamide-for-aml-undergoing-h 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-of-pleural-mesothelioma-asco-guideline-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-accurate-determinants-of-outcome-in-all 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-controlled-trial-of-a-virtually-delivered-exercise-and-stress-management-program-to-impro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/influence-of-nucleophosmin-inpm1i-genotypes-on-outcome-of-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pooled-long-term-outcomes-with-nivolumab-plus-ipilimumab-or-nivolumab-alone-in-patients-with-advance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/estimating-long-term-survivorship-rates-among-patients-with-resected-stage-iiiiv-melanoma-analyses 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chimeric-antigen-receptor-t-cells-in-colorectal-cancer-pioneering-new-avenues-in-solid-tumor-immuno 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-and-validation-of-data-driven-estimates-of-recurrence-risk-and-treatment-benefit-in-earl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-annual-versus-biennial-mammographic-screening-and-breast-cancer-screening-interval-eff 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hyperthermic-intraperitoneal-chemotherapy-in-platinum-sensitive-recurrent-ovarian-cancer-a-randomiz 2026-08-24 monthly 0.7 https://rjrindex.com/articles/withdrawn-expression-of-concern-dissecting-therapeutic-resistance-to-raf-inhibition-in-melanoma-by 2026-08-24 monthly 0.7 https://rjrindex.com/articles/high-omega-3-low-omega-6-diet-with-fish-oil-for-men-with-prostate-cancer-on-active-surveillance-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/promises-and-challenges-of-dietary-intervention-in-patients-with-prostate-cancer-lessons-learned-fr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/longitudinal-results-from-the-nationwide-just-ask-initiative-to-promote-routine-smoking-assessment-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-chemotherapy-for-newly-diagnosed-advanced-ovarian-cancer-asco-guideline-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clonal-hematopoiesis-in-women-with-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/onvansertib-in-combination-with-chemotherapy-and-bevacizumab-in-second-line-treatment-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/breast-cancer-screening-interval-effects-of-proportions-and-biases-on-benefits 2026-08-24 monthly 0.7 https://rjrindex.com/articles/zanubrutinib-versus-bendamustine-and-rituximab-in-patients-with-treatment-naive-chronic-lymphocytic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/you-dont-bring-me-flowers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-induction-or-consolidation-ch 2026-08-24 monthly 0.7 https://rjrindex.com/articles/navigating-gatekeeping-challenges-in-pediatric-and-young-adult-palliative-oncology-and-end-of-life-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/intermittent-or-continuous-panitumumab-plus-fluorouracil-leucovorin-and-irinotecan-for-first-line 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a-treatment-naive-chronic-lymphocyt 2026-08-24 monthly 0.7 https://rjrindex.com/articles/axillary-surgery-for-patients-with-residual-isolated-tumor-cells-ypn0i-after-neoadjuvant-systemic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/annual-versus-biennial-mammographic-screening 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nodal-burden-and-oncologic-outcomes-in-patients-with-residual-isolated-tumor-cells-after-neoadjuvant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-modified-infusional-fluorouracil-leucovorin-and-oxaliplatin-with-or-without-radiation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reneu-a-pivotal-phase-iib-trial-of-mirdametinib-in-adults-and-children-with-symptomatic-neurofibro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/redefining-available-therapy-in-oncology-accelerated-approval-decisions 2026-08-24 monthly 0.7 https://rjrindex.com/articles/human-leukocyte-antigen-mismatching-and-the-role-of-killer-cell-immunoglobulin-like-receptor-mismatc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-human-leukocyte-antigen-mismatching-and-the-role-of-killer-cell-immunoglobulin-like-recept 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comment-on-the-definition-and-interpretation-of-complete-mesocolic-excision-in-the-relarc-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-intensification-with-either-fludarabine-arac-g-csf-and-idarubicin-or-cladribine-plus-da 2026-08-24 monthly 0.7 https://rjrindex.com/articles/randomized-controlled-trial-of-acceptance-and-commitment-therapy-for-fatigue-interference-with-funct 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cyclin-dependent-kinase-46-inhibition-as-a-novel-therapy-for-peritoneal-mucinous-carcinomatosis-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-mek-inhibitor-shows-promise-in-neurofibromatosis-type-1-with-symptomatic-plexiform-neurofibro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/germline-and-somatic-genomic-testing-for-metastatic-prostate-cancer-asco-guideline 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-primary-cancer-risks-after-breast-cancer-in-ibrca1i-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-significance-of-up-front-stereotactic-radiosurgery-for-non-small-cell-lung-cancer-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/alk-tyrosine-kinase-inhibitors-induced-weight-gain-more-refined-definition-of-weight-gain-glucagon 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-comment-on-the-definition-and-interpretation-of-complete-mesocolic-excision-in-the-relarc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/body-weight-gain-associated-with-alectinib-in-patients-with-alk-non-small-cell-lung-cancer-pooled 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cost-effectiveness-of-total-neoadjuvant-therapy-with-selective-nonoperative-management-for-locally-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/significance-of-up-front-stereotactic-radiosurgery-for-non-small-cell-lung-cancer-patients-with-brai 2026-08-24 monthly 0.7 https://rjrindex.com/articles/accelerating-the-future-of-oncology-drug-development-the-role-of-consortia-in-the-delivery-of-preci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/large-scale-pharmacogenomics-analysis-of-patients-with-cancer-within-the-100000-genomes-project-com 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effectiveness-and-safety-of-first-line-atezolizumab-in-locally-advanced-or-metastatic-urothelial-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/head-to-head-comparison-of-micro-ultrasound-mpmri-and-psma-petct-with-a-wholemount-histopathology 2026-08-24 monthly 0.7 https://rjrindex.com/articles/implementing-indiana-regimen-salvage-high-dose-chemotherapy-in-relapsed-germ-cell-tumors-in-slovakia 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-systemic-treatments-for-advanced-non-clear-cell-renal-cell-carcinoma-a-single-arm-syste 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognosis-in-metastatic-renal-cell-cancer-mrcc-with-major-venous-involvement-mvi-a-population-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-post-radiotherapy-psa-as-a-prognostic-and-predictive-biomarker-in-high-risk-prostate-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/automated-classification-of-treatment-state-of-patients-with-prostate-cancer-from-structured-medical 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-evidence-from-a-retrospective-multi-center-analysis-on-first-line-therapy-for-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/role-of-liquid-biopsy-in-the-detection-of-homologous-recombination-repair-gene-mutations-hrrm-in-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/integrating-aggressive-variant-prostate-cancer-associated-tumor-suppressor-genes-avpc-tsg-status-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/oncological-benefit-of-avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/downregulation-of-e-selectin-and-contributions-to-immune-restraining-in-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-treatment-of-pancreatic-metastases-in-metastatic-renal-cell-carcinoma-insights-from-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/detection-of-early-stage-urothelial-cancers-using-methylation-patterns-in-urine-cell-free-dna 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comprehensive-bladder-cancer-molecular-profiling-and-monitoring-based-on-mutational-epigenomic-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/accel-ac-225-psma-62-phase-iaibii-clinical-trial-to-characterize-efficacy-safety-tolerability 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-analysis-of-2ir-immune-response-score-in-urothelial-carcinoma-uc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cabozantinib-c-in-combination-with-nivolumab-n-and-ipilimumab-i-in-previously-untreated-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/postoperative-adjuvant-treatment-of-her2-overexpression-in-upper-urinary-tract-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-enfortumab-vedotin-in-patients-with-previously-treated-advanced-head-and-neck-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-worldwide-disparities-in-bladder-cancer-clinical-trial-availability 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multicenter-open-label-phase-12-study-of-tyra-300-in-advanced-urothelial-carcinoma-and-other-sol 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-selective-renal-tumor-embolization-combined-with-axitinib-and-reduced-dose-toripalimab-i-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/external-validation-of-previously-reported-prognostic-classifications-for-patients-treated-with-seco 2026-08-24 monthly 0.7 https://rjrindex.com/articles/renal-cell-carcinoma-in-kidney-transplant-recipients-receiving-immunosuppression-a-55-year-retrospe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigation-of-ferroptosis-and-mtor-signaling-in-chromophobe-renal-cell-carcinoma-chrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-lutetium-177-vipivotide-tetraxetan-in-men-with-metastatic-castration-resistant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/management-of-metastatic-castration-resistant-prostate-cancer-mcrpc-at-the-veterans-affairs-health 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frequency-and-impact-of-a-genome-wide-homologous-recombination-deficiency-signature-hrdsig-on-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characteristics-and-clinical-outcomes-of-metastatic-testicular-cancer-in-a-distinct-demographic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/domain-specific-large-language-model-for-predicting-prostate-cancer-treatment-plan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/formula-01-a-phase-study-of-disitamab-vedotin-rc48-intravenous-injection-combined-with-bcg-intr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/quantifying-the-benefit-of-salvage-radiation-versus-surveillance-for-biochemically-recurrent-prostat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/grade-and-volume-progression-and-its-association-with-the-decipher-genomic-classifier-using-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/missed-opportunity-proms-as-primary-endpoints-in-bladder-cancer-trials 2026-08-24 monthly 0.7 https://rjrindex.com/articles/somatic-genomic-landscape-of-prostate-adenocarcinoma-at-a-comprehensive-cancer-center-in-new-mexico 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cabozantinib-real-world-effectiveness-in-the-second-line-setting-of-metastatic-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-patterns-in-prostate-cancer-patients-who-received-darolutamide-in-the-aramis-trial-in-spai 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-outcomes-with-belzutifan-versus-everolimus-by-baseline-disease-characteristics-and-burden-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-results-of-a-phase-2-study-of-neoadjuvant-chemotherapy-combined-with-tislelizumab-followed 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-sacituzumab-tirumotecan-monotherapy-in-patients-with-advanced-urothelial-carc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-checkpoint-inhibitors-icis-in-advanced-upper-tract-urothelial-cancer-utuc-with-mismatch-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1-first-in-human-dose-escalation-and-expansion-study-to-evaluate-the-safety-and-tolerabili 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-role-of-salvage-cystectomy-after-prior-trimodality-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decipher-score-as-a-predictor-of-response-to-treatment-intensification-in-the-nrg-oncology-rtog-0534 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assess-the-journey-characterizing-muscle-invasive-bladder-cancer-patients-who-receive-neoadjuvant-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-prognostic-impact-of-prostate-specific-antigen-at-6-months-after-post-prostatectomy-radiotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/defining-subgroups-of-patients-with-intermediate-risk-prostate-cancer-for-whom-active-surveillance-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-randomized-open-label-study-of-gemcitabinecisplatin-plus-cemiplimab-regn2810-anti-pd 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterizing-the-immune-effects-of-enfortumab-vedotin-ev-on-peripheral-blood-mononuclear-cells 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-disparities-in-prostate-cancer-in-the-caribbean-results-from-504-patients-from-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/understanding-health-inequalities-based-on-socio-economic-factors-and-geographical-location-in-renal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-fexagratinib-fexa-in-chinese-patients-pts-with-metastatic-or-unresectable 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-nature-of-progression-on-long-term-active-surveillance-for-confirmed-gleason-grade-group-1-prost 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avelumab-first-line-maintenance-1lm-in-patients-pts-with-advanced-urothelial-carcinoma-auc-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-influence-of-body-composition-on-the-survival-of-patients-with-metastatic-clear-cell-renal-carci 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-analysis-of-pembrolizumab-utilization-and-characteristics-of-patients-being-prescribed-tr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-survival-post-7-mo-psa-response-stratified-by-response-disease-extent-and-intermittent 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-myeloid-derived-suppressor-cell-mdsc-dynamics-with-clinical-response-to-nivolumab-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risk-stratification-using-the-decipher-22-gene-genomic-classifier-gc-and-digital-pathology-artific 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avelumab-first-line-1l-maintenance-treatment-in-patients-with-locally-advanced-or-metastatic-uroth 2026-08-24 monthly 0.7 https://rjrindex.com/articles/novel-urine-enriched-rna-panel-epcam-ttc3-h4c5-to-detect-prostate-cancer-and-differentiate-it-fr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-prior-primary-care-utilization-on-limiting-racial-disparities-for-prostate-cancer-diagnosi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-molecular-changes-and-perioperative-immunotherapy-in-patients-with-advanced-clea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/understanding-metastatic-squamous-cell-carcinoma-patients-receiving-pelvic-exenteration-vs-radical-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-associations-between-genomic-classifier-and-digital-pathology-based-multi-modal-ai-biomar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lenvatinibs-efficacy-in-heavily-pre-treated-metastatic-renal-cell-carcinoma-insights-from-a-europe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-inpatient-outcomes-of-bladder-cancer-2008-2021 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-use-and-outcomes-of-darolutamide-daro-enzalutamide-enza-and-apalutamide-apa-for-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/modulation-of-enhancer-of-zeste-homolog-2-ezh2-pharmacodynamic-markers-and-tumor-gene-expression-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-social-vulnerability-as-a-key-determinant-of-definitive-treatment-for-black-men-with-clin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/timely-brca-mutation-testing-in-patients-with-metastatic-prostate-cancer-a-comparative-analysis-bet 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-utility-of-measuring-steady-state-plasma-level-of-lenvatinib-in-advanced-renal-cell-carcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-role-of-cancer-associated-fibroblasts-in-t-cell-mediated-proinflammatory-reprogrammin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-time-to-metastasis-ttm-from-prostatectomy-and-survival-in-patients-pts-with-metach 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-tumor-burden-on-treatment-patterns-and-outcomes-in-patients-with-locally-advanced-or-metas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-in-metastatic-bladder-cancer-associated-with-mutations-in-trithorax-group-protein 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-outcomes-12-months-after-initiation-of-darolutamide-in-non-metastatic-castrate-resistant-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-pd-1-expression-on-tumor-infiltrating-regulatory-t-cells-and-resistance-to-first 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-efficacy-of-enfortumab-vedotin-pembrolizumab-ev-p-in-locally-advanced-la-or-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-clear-cell-renal-cell-carcinoma-tumor-infiltrating-lymphocytes-under-controlled-hypoxic-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/final-overall-survival-os-with-talazoparib-tala-enzalutamide-enza-as-first-line-treatment-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/body-composition-and-immunotherapy-outcomes-in-patients-with-advanced-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-significance-of-urotensin-2-plasma-level-in-patients-diagnosed-with-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-iparp1i-mrna-expression-as-prognostic-of-aggressive-patho 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gut-microbiota-as-a-biomarker-for-the-efficacy-of-pembrolizumab-in-patients-with-advanced-urothelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bone-metastases-and-use-of-bone-protective-agents-bpa-for-metastatic-renal-cell-carcinoma-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-disparities-in-renal-cell-carcinoma-histology-and-outcomes-insights-from-the-french-kidney-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-line-platinum-based-chemotherapy-pbt-in-patients-with-metastatic-urothelial-carcinoma-muc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recent-treatment-patterns-in-us-based-real-world-patients-pts-with-metastatic-hormone-sensitive-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-deephrd-interpretability-for-enhanced-clinical-decision-making 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterizing-immunogenicity-of-imyc-i-amplified-metastatic-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-effect-of-circadian-rhythm-based-medication-timing-adjustments-on-the-efficacy-and-safety-of-nov 2026-08-24 monthly 0.7 https://rjrindex.com/articles/site-specific-disease-progression-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-firs 2026-08-24 monthly 0.7 https://rjrindex.com/articles/homologous-recombination-deficiency-signature-hrdsig-and-the-genomic-landscape-of-clinically-adva 2026-08-24 monthly 0.7 https://rjrindex.com/articles/machine-learning-model-integrating-ct-radiomics-and-circulating-micrornas-to-predict-residual-diseas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/time-burden-and-healthcare-costs-associated-with-docetaxel-in-patients-with-metastatic-castration-se 2026-08-24 monthly 0.7 https://rjrindex.com/articles/differences-in-health-related-quality-of-life-between-rural-and-urban-bladder-cancer-patients-follow 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-impact-of-first-line-1l-chemotherapy-cycles-in-patients-with-metastatic-urothelial-carc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-analysis-of-active-surveillance-for-japanese-young-early-stage-prostate-cancer-patients-from-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adherence-to-clinical-surveillance-guidelines-in-von-hippel-lindau-vhl-disease-evaluating-the-imp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/individualized-neoantigen-vaccine-with-nivolumab-plus-cabozantinib-for-translocation-renal-cell-carc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-invasive-primary-urethral-cancer-a-real-world-multi-institutional-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-treatment-and-survival-outcomes-of-penile-cancer-over-a-decade-in-a-tertiary-mexi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-brca-status-in-patients-with-castrate-resistant-prostate-cancer-undergoing-abiraterone 2026-08-24 monthly 0.7 https://rjrindex.com/articles/barriers-to-and-facilitators-of-first-line-treatment-intensification-ti-in-metastatic-castration-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/eortc-gucg-2418-starburst-strategies-for-treatment-adaptation-following-re-evaluation-of-the-blad 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-results-from-a-phase-iii-study-of-cbp-1018-a-bi-ligand-drug-conjugate-bi-xdc-as-late-lin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nectin-4-targeted-adc-shr-a2102-in-patients-with-advanced-or-metastatic-urothelial-carcinoma-a-ph 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-time-on-treatment-rwtot-with-first-line-1l-enfortumab-vedotin-and-pembrolizumab-evp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/retrospective-observational-analysis-of-real-world-safety-outcomes-in-sacituzumab-govitecan-sg-tr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/deep-prostate-specific-antigen-psa-decline-among-early-participants-pts-in-libertas-a-phase-3-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/persian-trial-early-results-from-a-randomized-phase-ii-trial-testing-apalutamide-and-stereotactic-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/keymaker-u03-substudy-03b-pembrolizumab-pembro-and-targeted-therapy-combinations-for-advanced-cle 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lenvatinib-plus-tislelizumab-as-first-line-therapy-for-advanced-fumarate-hydratase-deficient-renal-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/regional-and-racial-disparities-in-testicular-cancer-related-mortality-among-hivaids-adults-in-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/low-dose-abiraterone-in-metastatic-castration-resistant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-loss-of-prlhr-on-aneuploidy-and-initiation-of-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/platelet-to-lymphocyte-ratio-as-a-useful-biomarker-of-recurrence-and-mortality-risks-in-patients-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-checkpoint-inhibitors-in-patients-with-testicular-cancer-a-systematic-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-fruquintinib-combined-with-serplulimab-as-1-supstsup 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-neoadjuvant-intravesical-mitomycin-c-in-nmibc-a-phase-iii-randomized-clinical-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-feasibility-of-tumor-infiltrating-lymphocyte-expansion-in-non-clear-cell-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prognostic-biomarker-panel-for-chromophobe-renal-cell-carcinoma-using-immunohistochemistry 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-differences-in-organic-anion-transport-proteins-oatp-and-outcome-in-castration-resistant-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sociodemographic-disparities-in-treatment-tx-patterns-and-clinical-outcomes-among-real-world-patie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-analysis-of-the-efficacy-and-safety-of-enfortumab-vedotin-in-patients-with-locally-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prostate-cancer-liver-metastases-genomic-profiling-and-clinical-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/how-unfavorable-is-aua-unfavorable-intermediate-risk-prostate-cancer-results-from-a-large-institut 2026-08-24 monthly 0.7 https://rjrindex.com/articles/olanzapine-for-managing-side-effects-from-tyrosine-kinase-inhibitors 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-homologous-recombination-repair-alterations-ihrralti-on-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/time-to-metastasis-after-prostatectomy-ttm-and-survival-outcomes-in-patients-pts-with-metachrono 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-of-an-mirna-signature-for-individual-prognostic-assessment-in-seminoma-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/t-suppression-and-recovery-with-aap-after-early-discontinuation-of-lhrh-a-in-high-risk-localized-hr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-evidence-from-a-retrospective-multi-center-analysis-on-first-line-therapy-for-metastatic-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-12-study-of-nezastomig-anti-psmacd28-with-or-without-cemiplimab-anti-pd-1-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-systemic-therapy-for-small-cell-lung-cancer-asco-guideline-rapid-recommendation-update 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-real-world-data-evaluation-of-clinical-outcomes-in-metastatic-hormone-sensitive-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/development-of-a-fksi-23-a-new-bespoke-health-related-quality-of-life-hrqol-questionnaire-for-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-iii-single-arm-study-to-evaluate-the-efficacy-and-safety-of-paclitaxel-hyaluronic-acid-conju 2026-08-24 monthly 0.7 https://rjrindex.com/articles/epic-a-phase-ii-trial-of-cemiplimab-plus-standard-of-care-chemotherapy-followed-by-maintenance-cemi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-immune-checkpoint-inhibitors-ici-for-the-treatment-of-metastatic-penile-squ 2026-08-24 monthly 0.7 https://rjrindex.com/articles/final-overall-survival-of-aries-trial-evaluating-first-line-avelumab-monotherapy-for-patients-with-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-tolerability-of-relugolix-in-combination-with-abiraterone-or-apalutamide-for-treatment-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-radiation-therapy-to-the-recurrence-sites-and-oncological-outcomes-in-patients-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sup68sup-ga-fapi-46-petct-for-cancer-imaging-results-of-a-single-center-prospect 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-significance-of-androgen-receptor-signaling-pathway-in-mcrpc-patients-receiving-olaparib-monothe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/improving-prostate-cancer-risk-stratification-using-spatial-single-cell-tumor-profiling 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avelumab-maintenance-therapy-in-patients-pts-with-advanced-urothelial-carcinoma-uc-in-japan-sub-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathological-complete-response-and-potential-for-bladder-preservation-by-theranostic-instillation-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analysis-of-gene-expression-signatures-in-prostate-cancer-prior-to-liver-metastases 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ocog-rational-a-phase-ii-randomized-trial-of-optimal-recurrence-directed-therapy-rdt-without-or-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-i-dose-escalation-study-of-the-next-generation-nectin-4-targeting-antibody-drug-conjugate-crb 2026-08-24 monthly 0.7 https://rjrindex.com/articles/approach-to-treatment-of-metastatic-hormone-sensitive-prostate-mhspc-cancer-among-cooperative-onco 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-and-efficacy-of-cisplatin-based-neoadjuvant-chemotherapy-for-muscle-invasive-bladder-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-novel-cd28-x-nectin-4-costimulatory-bispecific-antibody-for-advanced-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/further-optimizing-care-of-patients-with-operable-hormone-receptor-sensitive-breast-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/modeling-survival-outcomes-of-keynote-564-with-standard-of-care-control-arm-treatment-a-simulation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cognitive-effects-of-androgen-receptor-ar-directed-therapies-for-advanced-cancer-of-the-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-effectiveness-and-treatment-tx-patterns-in-patients-pts-with-locally-advancedmetasta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mevrometostat-pf-06821497-in-combination-with-enzalutamide-in-patients-with-metastatic-castration 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-double-blind-placebo-controlled-2-cohort-randomized-study-of-saruparib-azd5305-in-co 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metastases-directed-therapy-in-addition-to-standard-systemic-therapy-in-oligometastatic-castration-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-iii-study-of-neoadjuvant-intra-arterial-administration-of-177lulutetium-vipivotide-tetra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-first-in-human-phase-1-study-of-ly3866288-loxo-435-a-potent-highly-isoform-selective-fgfr3-inh 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mass-cytometry-based-deep-immune-cell-profiling-of-metastatic-clear-cell-renal-cell-carcinoma-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/omaha-003-a-phase-3-study-of-cyp11a1-inhibitor-opevesostat-versus-next-generation-hormonal-agent-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-molecular-alteration-profiles-to-distinguish-intraductal-carcinoma-of-the-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/vorsin-rcc-vorolanib-plus-sintilimab-for-advanced-renal-cell-carcinoma-after-failure-of-prior-immun 2026-08-24 monthly 0.7 https://rjrindex.com/articles/99mtctc-ipsma-spectct-as-an-alternative-to-pet-imaging-for-decision-making-in-prostate-cancer-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multivisceral-surgery-in-patients-with-locally-advanced-castration-naive-and-castration-resistant-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/health-related-quality-of-life-in-patients-with-metastatic-prostate-cancer-results-from-an-internat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-the-strategies-to-perform-prostate-biopsy-in-mri-positive-patients-a-systematic-review-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/timely-next-generation-sequencing-testing-in-patients-with-metastatic-prostate-cancer-a-comparative 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-therapeutic-role-of-lymph-node-dissection-in-variant-histology-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/biomarker-analysis-in-localized-urothelial-cancer-duart-patients-post-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-trial-of-immuno-ablation-with-intrabladder-injection-of-n-803-or-intravesical-n-803-plus-bcg 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utilization-healthcare-expenditures-and-patient-costs-of-definitive-treatment-modalities-for-local 2026-08-24 monthly 0.7 https://rjrindex.com/articles/boosting-survival-in-advanced-urothelial-carcinoma-the-power-of-cbm588-probiotic-and-pembrolizumab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/serum-biomarkers-in-metastatic-castration-resistant-prostate-cancer-mcrpc-patients-receiving 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-of-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-with-ugn-102-results-of-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/automated-risk-stratification-in-localized-prostate-cancer-using-an-ai-assisted-framework 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-pembrolizumab-pembro-and-accelerated-methotrexate-vinblastine-doxorubicin-cisplatin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-of-combining-radiotherapy-and-antibody-drug-conjugates-in-advanced-urothelial-and-other-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/upstaging-and-risk-migration-with-blue-light-cystoscopy-for-non-muscle-invasive-bladder-cancer-resu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-relative-dose-intensity-on-efficacy-of-enfortumab-vedotin-monotherapy-in-platinum-and-ici 2026-08-24 monthly 0.7 https://rjrindex.com/articles/apatinib-monotherapy-for-pretreated-advanced-squamous-cell-carcinoma-of-the-penis-a-phase-ii-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inclusion-of-patients-with-reduced-performance-status-ecog-2-or-higher-in-fda-registrational-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preliminary-efficacy-and-safety-of-disitamab-vedotin-dv-combined-with-bacillus-calmette-guerin-bc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-interpath-005-study-v940-mrna-4157-plus-pembrolizumab-with-or-without-enfortumab-vedoti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinically-advanced-prostate-cancer-capc-in-extremely-young-men-a-genomic-landscape-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-site-of-metastases-and-survival-stratification-of-the-imdc-classification-in-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/risk-factors-of-complications-after-inguinal-lymph-node-dissection-in-patients-with-penile-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/plasma-proteome-based-integrative-prognostic-nomogram-in-metastatic-castrate-resistant-prostate-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/unraveling-the-dietary-impact-associations-between-ultra-processed-foods-and-prostate-cancer-in-a-t 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-community-oncology-based-treatment-patterns-for-first-line-axitinib-plus-pembrolizumab-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-disparities-by-race-in-advanced-urothelial-carcinoma-auc-a-real-world-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-profiling-at-the-single-cell-level-to-evaluate-the-immune-microenvironment-in-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-comparison-of-cost-and-adherence-between-patients-receiving-low-dose-versus-standard-dose 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-next-generation-sequencing-ngs-testing-at-the-end-of-life-in-patients-with-metastatic-prosta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-term-outcomes-of-neoadjuvant-chemotherapy-nac-before-bladder-sparing-chemoradiotherapy-crt 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-high-ctdna-tumor-fraction-tf-and-detection-of-clinically-significant-copy-number-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-of-cabozantinib-and-nivolumab-in-metastatic-castration-resistant-prostate-cancer-ca-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/heterogeneity-in-subgroup-reporting-across-clinical-trials-assessing-systemic-therapies-in-metastati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-impact-of-social-vulnerability-on-perceived-health-in-individuals-with-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multicenter-analysis-of-high-dose-chemotherapy-hdct-regimens-for-recurrent-germ-cell-tumors-gcts 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ai-driven-prediction-of-prostate-cancer-risk-a-comparative-analysis-with-c-the-signs-in-the-mayo-cl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chronic-obstructive-pulmonary-disease-mortality-risk-in-renal-cell-carcinoma-a-population-based-stu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-of-testicular-cancer-tc-in-hispanic-men-based-on-analyses-from-the-national-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-physicians-awareness-of-prostate-specific-antigen-doubling-time-psadt-on-treatment-tx 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-cardiovascular-cv-toxicity-by-providers-in-advanced-prostate-cancer-pca-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-cotrims-cologne-trial-of-retroperitoneal-lymphadectomy-in-metastatic-seminoma-trial-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1b-open-label-multicenter-study-of-xaluritamig-in-patients-with-biochemical-recurrence-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/initial-report-of-a-randomized-trial-of-post-prostatectomy-prostate-cancer-radiotherapy-using-either 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-of-adverse-events-following-t-cell-engaging-bispecific-antibodies-bsabs-and-chimeric-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/docetaxel-rechallenge-versus-cabazitaxel-in-patients-previously-treated-with-docetaxel-for-metastati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enfortumab-vedotin-related-skin-toxicities-in-patients-with-urothelial-carcinoma-a-systematic-revie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-treatment-with-disitamab-vedotin-plus-perioperative-toripalimab-in-patients-with-muscle 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-study-of-regn4336-alone-or-in-combination-with-cemiplimab-or-nezastomig-in-patients-pts 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-tumor-response-to-enfortumab-vedotin-withwithout-pembrolizumab-in-patients-with-upper-tract 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-of-sup177sup-lu-psma-617-psma-in-a-racially-diverse 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pet-imaging-for-metastatic-castration-sensitive-prostate-cancer-mcspc-for-patients-with-psa-respon 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-testosterone-recovery-after-androgen-deprivation-therapy-on-overall-survival-in-patients-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1-first-in-human-open-label-dose-escalating-study-of-b440-an-oral-cancer-vaccine-using-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-12-study-of-detalimogene-voraplasmid-eg-70-intravesical-monotherapy-for-patients-with-hig 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-monitoring-of-prostate-specific-membrane-antigen-psma-positive-recurrent-prostate-can 2026-08-24 monthly 0.7 https://rjrindex.com/articles/implementation-of-a-digital-multimedia-tool-for-prostate-cancer-patient-consultation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-efficacy-and-safety-of-pelvic-lymph-node-dissection-in-high-risk-prostate-cancer-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/population-based-assessment-of-treatment-patterns-for-high-risk-localized-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-patients-with-stage-i-testicular-cancer-following-orchidectomy-with-borderline-retroperi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/immune-and-inflammatory-profiling-in-bladder-cancer-insights-into-biomarkers-and-therapeutic-strate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clarify-positron-emission-tomography-using-sup64sup-cu-sar-bispsma-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-androgen-deprivation-therapy-with-postoperative-radiotherapy-after-radical-prostatectomy-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phenotypic-and-genetically-predicted-leukocyte-telomere-length-and-prostate-cancer-risk-results-fro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hif2a-gene-expression-and-clinical-outcomes-in-patients-with-clear-cell-renal-cell-carcinoma-with-an 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mental-health-monitoring-in-clinical-trials-for-fda-approved-genitourinary-cancer-treatments-a-deca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-effectiveness-and-safety-of-avelumab-first-line-maintenance-1lm-treatment-in-patients-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concordance-of-circulating-tumor-dna-and-imaging-surveillance-in-patients-with-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-the-soluble-epoxide-hydrolase-seh-enzyme-to-relieve-painful-docetaxel-induced-peripheral 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-of-de-novo-mhspc-based-on-hemoglobin-a1c-and-arpi-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analysis-of-distinct-genomic-transcriptomic-and-immune-landscapes-driven-by-alterations-in-androge 2026-08-24 monthly 0.7 https://rjrindex.com/articles/difference-in-renal-cell-carcinoma-rcc-prevalence-between-kidney-transplant-versus-other-solid-org 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-comparative-analysis-of-complication-rates-in-urinary-diversions-exploring-the-impact-of-contempo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-rw-treatment-tx-patterns-and-clinical-outcomes-in-patients-pts-with-metastatic-rena 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adjuvant-nivolumab-nivo-vs-placebo-pbo-for-high-risk-muscle-invasive-urothelial-carcinoma-miuc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1-dose-escalation-des-amp-expansion-dex-study-to-evaluate-the-safety-amp-efficacy-of-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decipher-risk-stratification-of-radiorecurrent-prostate-cancer-correlative-analysis-of-the-f-sharp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mevrometostat-pf-06821497-in-combination-with-enzalutamide-for-androgen-receptor-pathway-inhibitor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concomitant-g-csf-use-in-maintaining-an-efficacious-dose-and-safe-delivery-of-docetaxel-in-combinati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prostact-global-a-phase-3-study-of-sup177sup-lu-rosopatamab-tlx591-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-liquid-biopsy-based-proteomic-assay-to-identify-circulating-tumor-cell-ctc-derived-druggable-ta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/decipher-genomic-classifier-dgc-of-early-prostate-cancer-epc-and-underlying-transcriptomic-prof 2026-08-24 monthly 0.7 https://rjrindex.com/articles/carcinoma-of-prostate-sequencing-of-tumor-and-clinical-endpoints-capstone-clinical-implications-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comorbidity-burden-and-effectiveness-of-immunotherapy-in-patients-with-metastatic-renal-cell-carcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/contemporary-post-prostatectomy-radiation-therapy-for-prostate-cancer-within-a-statewide-quality-con 2026-08-24 monthly 0.7 https://rjrindex.com/articles/expression-of-tissue-factor-tf-in-penile-squamous-cell-carcinoma-pscc-and-enrichment-in-hpv-nega 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-in-advanced-prostate-cancer-pca-patients-with-visceral-metastasis-a-population-based-see 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-io-tki-vs-io-io-combinations-in-imdc-poor-risk-metastatic-renal-cell-carcinoma-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/receipt-of-polyadp-ribose-polymerase-inhibitors-parpi-in-patients-pts-with-metastatic-castrati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prospective-provincial-registry-of-psma-pet-ct-for-recurrent-prostate-cancer-prep-results-for-4 2026-08-24 monthly 0.7 https://rjrindex.com/articles/interim-analysis-of-the-shutter-speed-mri-model-to-detect-clinically-significant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/primary-sarcomas-of-urinary-bladder-a-seer-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-high-omega-3-low-omega-6-diet-with-fish-oil-for-men-with-prostate-cancer-on-active-surveillance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-use-of-bone-modifying-agents-bma-in-patients-pts-with-metastatic-castration-resistant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/modified-transurethral-resection-of-bladder-tumors-a-comparison-study-of-chemotherapy-enhanced-endo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/punch01-interim-results-from-a-phase-ii-study-of-intra-arterial-chemotherapy-iac-combined-with-ti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-insurance-type-on-outcomes-after-radical-cystectomy-for-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-and-predictive-genomic-biomarkers-in-metastatic-clear-cell-renal-cell-carcinoma-mccrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-patterns-and-outcomes-of-novel-androgen-receptor-axis-targeted-agents-in-non-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterizing-the-clinical-and-genomic-features-of-androgen-indifferent-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/non-muscle-invasive-bladder-cancer-treatment-selection-in-an-emerging-treatment-era-a-patient-prefe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bayesian-re-analysis-comparing-radical-cystectomy-with-trimodality-therapy-in-patients-with-muscle 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-use-and-outcomes-of-androgen-receptor-pathway-inhibitors-triplet-therapy-for-metastatic-hor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tumor-necrosis-factor-alpha-signaling-activity-and-nccn-risk-adverse-pathology-and-progression-dur 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neo-blast-neoadjuvant-therapy-for-bladder-cancer-followed-by-active-surveillance-vs-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-disitamab-vedotin-combined-with-toripalimab-as-neoadjuvant-treatment-for-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-i-first-in-human-clinical-trial-with-plz4-coated-paclitaxel-loaded-micelles-ppm-in-therapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/g-disco-gemcitabine-docetaxel-intravesical-instillation-synchronous-co-administration-a-phase-i-stu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/therapeutic-approaches-and-outcomes-in-patients-aged-50-with-germ-cell-tumours 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-in-metastatic-prostate-cancer-patients-with-ctdna-detected-ispop 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-impact-of-the-area-deprivation-index-on-immunotherapy-outcomes-in-metastatic-renal-cell-carcinom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-analysis-of-ar-v7-expression-in-patients-pts-with-metastatic-castration-resistant-pros 2026-08-24 monthly 0.7 https://rjrindex.com/articles/igi-rate-based-machine-learning-model-to-predict-overall-survival-os-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/theratest-a-multi-centre-observational-cohort-feasibility-study-of-de-escalation-therapies-for-stag 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avelumab-in-combination-with-axitinib-ave-axi-for-first-line-1l-treatment-of-advanced-renal-ce 2026-08-24 monthly 0.7 https://rjrindex.com/articles/implementing-precision-oncology-in-renal-cell-carcinoma-rcc-prospective-identification-of-clinica 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ib-window-of-opportunity-study-of-atezolizumab-administered-intravesically-or-direct-injecti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-psma-pet-staging-on-initial-treatment-in-newly-diagnosed-prostate-cancer-an-emulated-rand 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-fgfr-inhibitors-in-urothelial-carcinoma-a-systematic-review-and-meta-analysi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/state-of-the-genitourinary-medical-oncology-workforce-in-the-united-states-2024 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-protocols-to-monitor-efficacy-of-sup177sup-lulu-psma-radiop 2026-08-24 monthly 0.7 https://rjrindex.com/articles/artificial-intelligence-derived-tumor-volume-from-baseline-mri-and-postprostatectomy-outcomes-follow 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utility-of-post-treatment-spectct-for-identifying-disease-progression-in-patients-with-mcrpc-treate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/exploring-social-vulnerability-in-prostate-cancer-management-insights-into-utilization-of-watchful 2026-08-24 monthly 0.7 https://rjrindex.com/articles/age-related-efficacy-and-safety-of-darolutamide-plus-androgen-deprivation-therapy-adt-and-docetaxe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-3-omaha-004-study-of-cyp11a1-inhibitor-opevesostat-versus-next-generation-hormonal-agent-nha 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-patterns-and-survival-in-men-with-metastatic-castration-resistant-prostate-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-and-caregiver-preferences-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-car 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-effectiveness-and-safety-of-first-line-1l-avelumab-axitinib-in-patients-with-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/post-chemotherapy-retroperitoneal-lymph-node-dissection-pc-rplnd-for-metastatic-pure-seminoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/understanding-incidence-and-outcomes-of-testicular-and-ovarian-germ-cell-tumors-from-2000-2017-using 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevalence-of-germline-variants-of-uncertain-significance-in-dna-repair-genes-and-their-potential-im 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-insights-of-low-psa-expressing-high-risk-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-value-of-quantitative-psma-pet-parameters-during-chemotherapy-in-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-impact-of-germline-deleterious-variants-and-variants-of-uncertain-significance-in-advance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/low-versus-low-intermediate-risk-metastatic-renal-cell-carcinoma-mrcc-contemporary-data-from-the 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-contribution-of-circulating-tumor-dna-ctdna-towards-magnetic-resonance-imaging-mri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/inectin4i-rna-expression-and-clinical-outcomes-with-first-line-1l-platinum-based 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pro-xl-a-phase-ii-study-of-zanzalintinib-xl092-in-patients-with-metastatic-castration-resistant-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-23-multicenter-trial-evaluating-safety-and-efficacy-of-a-new-mucoadhesive-gemcitabine-suspe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/tislelizumab-in-combination-with-abirateroneenzalutamide-for-metastatic-castration-resistant-prosta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-persistence-and-adherence-to-relugolix-rel-in-us-patients-with-nonmetastatic-nm-vs-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/application-of-radiomics-as-a-risk-stratification-tool-in-node-positive-penile-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/adrenal-androgens-and-overall-survival-os-in-men-with-castration-resistant-prostate-cancer-crpc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frequent-overexpression-of-nectin-4-in-cns-metastases-from-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-kidney-cancer-exploring-the-impact-of-sex-and-age-on-stage-of-disease-and-prognosis-duri 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-pattern-and-clinical-outcomes-among-patients-with-metastatic-renal-cell-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-prevalence-and-outcomes-of-androgen-receptor-ligand-binding-domain-mutations-in-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/keymaker-u03-substudy-03b-pembrolizumab-pembro-and-novel-immunotherapy-agents-for-advanced-clear 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-for-sup177sup-lu-psma-617-with-and-without-concurrent-use-of-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-toxicity-and-cosmesis-of-partial-breast-irradiation-honing-in-on-dose-and-patient-select 2026-08-24 monthly 0.7 https://rjrindex.com/articles/can-magnetic-resonance-imaging-safely-replace-a-confirmatory-biopsy-in-patients-on-active-surveillan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/recurrence-and-its-association-with-overall-survival-os-in-muscle-invasive-bladder-cancer-mibc-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-follow-up-of-a-randomized-double-blinded-phase-ii-study-of-ketoconazole-keto-hydrocortis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-toxicity-profile-of-antibody-drug-conjugate-adc-based-combination-therapy-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/enfortumab-vedotin-plus-pembrolizumab-in-metastatic-urothelial-carcinoma-first-results-on-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ibiia-dose-escalation-and-expansion-study-of-sup212sup-pbpb-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-trial-of-risk-enabled-therapy-after-neoadjuvant-chemo-immunotherapy-for-muscle-invasive-bl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cobra-assessment-of-the-efficacy-of-sup64sup-cu-sar-bispsma-using-hist-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glp1r-expression-in-prostate-cancer-patients-and-effects-of-glp1r-agonism-on-prostate-cancer-cells 2026-08-24 monthly 0.7 https://rjrindex.com/articles/utilizing-chatgpt-for-assessing-disease-volume-in-patients-pts-with-metastatic-prostate-cancer-mp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-covid-19-pandemic-on-the-treatment-of-prostate-cancer-in-brazilian-public-health-system-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-of-stage-iiaiib-seminoma-treated-with-radiotherapy-and-chemotherapy-should-regio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-disparities-by-sex-with-contemporary-advanced-urothelial-carcinoma-auc-therapy-a-real-wo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impaired-renal-function-and-cisplatin-based-regimens-as-risk-factors-for-neoadjuvant-chemotherapy-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-dna-as-a-prognostic-biomarker-to-predict-retroperitoneal-histology-in-patients-und 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-significance-of-tumor-immune-microenvironment-dynamics-in-prostate-cancer-induced-by-andr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-impact-of-a-community-based-prostate-cancer-screening-program 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-molecular-heterogeneity-of-prostate-cancer-biopsy-sampling-insights-from-the-mast-trial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-combination-of-vi-rads-based-on-t2wi-and-morphological-features-and-pathological 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-study-of-oral-apl-1202-plus-tislelizumab-or-tislelizumab-alone-as-neoadjuvant-therapy-in-pa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathogenic-germline-variant-prevalence-and-genetic-testing-outcomes-in-patients-with-urothelial-carc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/nectin-4-and-trop-2-expression-as-potential-therapeutic-target-in-collecting-duct-carcinoma-prelimi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cupid-sup64sup-cu-tlx592-phase-i-pk-biodistribution-and-dosimetry-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/time-to-real-world-progression-ttrwp-among-patients-pts-with-relapsedrefractory-rr-testicula 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effectiveness-and-safety-of-radium-223-in-men-with-metastatic-castration-resistant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rucaparib-vs-docetaxel-dtx-or-second-generation-androgen-pathway-inhibitor-arpi-therapy-for-meta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/additional-efficacy-and-safety-outcomes-and-an-exploratory-analysis-of-the-impact-of-pathological-co 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cadonilimab-combined-with-lenvatinib-for-neoadjuvant-therapy-in-early-stage-renal-cell-carcinoma-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optyx-study-clinical-characteristics-and-preferences-for-initiating-relugolix-in-a-cohort-of-us-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prognostic-model-for-survival-of-patients-with-metastatic-upper-tract-urothelial-carcinoma-with-fi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-mir-371a-3p-for-clinical-implementation-in-a-clia-certified-laboratory 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validation-of-a-15-gene-prognostic-signature-in-metastatic-clear-cell-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comprehensive-modalities-of-kidney-sparing-treatment-in-a-carefully-selected-cohort-of-localized-hig 2026-08-24 monthly 0.7 https://rjrindex.com/articles/identification-of-potential-immune-evasion-mechanisms-in-aggressive-small-renal-cell-carcinomas-thro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-psma-pet-and-conventional-imaging-on-contemporary-management-in-patients-with-biochemical 2026-08-24 monthly 0.7 https://rjrindex.com/articles/who-undergoes-cytoreductive-nephrectomy-now-an-analysis-of-perioperative-risk-characteristics-in-co 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-adding-immunotherapy-to-chemotherapy-for-metastatic-neuroendocrine-bladder-cancer-in-the-n 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-iii-randomized-trial-of-stereotactic-ablative-radiotherapy-sabr-for-oligometastatic-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prostate-cancer-supportive-care-pcsc-program-an-alternative-to-consolidated-framework-for-impleme 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-epidemiology-and-clinical-outcomes-of-bladder-cancer-patients-in-spain-blarwe-multicente 2026-08-24 monthly 0.7 https://rjrindex.com/articles/leep-a-randomised-window-of-opportunity-neoadjuvant-trial-examining-the-pharmacodynamic-effects-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-profiles-as-drivers-of-physician-choice-for-first-line-1l-treatment-tx-in-locally-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/relationship-between-androgen-deprivation-therapy-and-kidney-function-in-patients-with-prostate-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/germline-genetic-variants-in-cancers-of-the-urothelial-tract-and-association-with-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-trial-of-dostarlimab-and-niraparib-combination-therapy-in-patients-with-stage-iii-iv-recu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-disparities-in-prostate-cancer-related-mortality-among-diabetic-adults-in-the-united-stat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-tislelizumab-t-combined-with-gemcitabine-and-cisplatin-gc-for-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-an-integrated-germline-polygenic-and-clinical-risk-model-p-care-specifically-for-aggres 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-disparities-in-secondary-metastasis-in-patients-with-bladder-cancer-a-5-year-national-inpati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-role-of-cytoreductive-radical-prostatectomy-in-the-management-of-patients-with-metastatic-hormon 2026-08-24 monthly 0.7 https://rjrindex.com/articles/radiographic-progression-without-psa-progression-in-advanced-prostate-cancer-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-man-van-phase-2-results-mobile-targeted-case-finding-for-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/global-and-regional-burden-of-kidney-cancer-analysis-and-future-predictions-based-on-gbd-data-from 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-subtypes-inectin4her2i-expression-and-clinical-outcomes-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neuropathy-skin-rash-and-hyperglycemia-as-predictors-of-response-to-enfortumab-vedotin-in-locally 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dose-finding-study-of-cbm588-in-combination-with-nivolumab-and-ipilimumab-in-patients-with-metastati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/darolutamide-plus-adt-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc-by-disea 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-treatment-patterns-and-outcomes-in-advanced-prostate-cancer-a-cohort-study-using-the-pro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-cell-ctc-expression-patterns-of-cell-surface-targets-in-metastatic-prostate-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cabozantinib-c-atezolizumab-a-in-patients-pts-with-metastatic-castration-resistant-prostate 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-de-novo-oligometastatic-prostate-cancer-patients-managed-with-radiation-therapy-a-mul 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-reported-outcomes-pros-for-tivozanib-tivo-nivolumab-nivo-vs-tivo-monotherapy-in-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-prognostic-value-of-ldh-in-patients-with-good-risk-metastatic-seminoma-treated-with-single-agent 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ctc-and-ar-v7-analysis-in-the-ecog-acrin-8153-chaarted2-randomized-trial-abiraterone-abi-with-o 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-variant-allele-frequency-vaf-of-itp53i-alterations-and-sign 2026-08-24 monthly 0.7 https://rjrindex.com/articles/temporal-trends-and-socioeconomic-determinants-of-cytoreductive-nephrectomy-cn-utilization-for-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-dna-ctdna-monitoring-in-the-assessment-and-prediction-of-the-efficacy-of-parp-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/variants-of-unknown-significance-vus-in-dna-repair-genes-in-caucasian-men-with-muscle-invasive-bla 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bacillus-calmette-guerin-bcg-treatment-patterns-and-real-world-outcomes-in-high-risk-hr-non-musc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-more-than-tumors-the-impact-of-enfortumab-vedotin-and-pembrolizumab-evp-on-skeletal-mu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-effectiveness-of-systemic-treatment-in-patients-pts-with-advanced-upper-tract-urothelia 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avenance-real-world-study-of-avelumab-first-line-1l-maintenance-treatment-for-advanced-urothelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/androgen-receptor-activity-in-biopsy-specimens-at-initial-diagnosis-of-prostate-cancer-and-correlati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-salvage-lymph-node-dissection-in-prostate-cancer-patients-with-nodal-recurren 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparing-the-effectiveness-of-io-based-combination-regimens-as-first-line-treatment-for-advanced-cl 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-ifosfamide-and-mesna-in-metastatic-castration-resistant-prostate-cancer-after 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-baseline-psma-pet-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/equal-depth-sequencing-of-white-blood-cells-wbc-and-plasma-from-prostate-cancer-pca-liquid-biops 2026-08-24 monthly 0.7 https://rjrindex.com/articles/casdatifan-cas-monotherapy-in-patients-pts-with-previously-treated-clear-cell-renal-cell-carcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-rx-patterns-and-attrition-rates-in-patients-pts-with-metastatic-castration-resistant-p-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-of-enriched-amplicon-circulating-tumor-dna-sequencing-to-detect-minimal-residual-disease 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-randomized-study-of-high-risk-metachronous-oligometastatic-prostate-cancer-with-high-risk-mu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/global-real-world-patients-characteristics-treatment-patterns-and-impact-of-bcg-shortage-in-patien 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trastuzumab-duocarmazine-in-pretreated-human-epidermal-growth-factor-receptor-2-positive-advanced-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-toxicity-profile-of-enfortumab-vedotin-ev-with-or-without-pembrolizumab-p-in-ultra-el 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-characteristics-and-survival-in-primary-prostate-sarcomas-an-analysis-of-the-seer-database 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-iii-study-testing-the-role-of-proactive-coaching-on-patient-reported-outcome-in-advanced-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-prognostic-utility-of-preoperative-v2-microglobulin-in-patients-with-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-novel-predictive-model-using-changes-in-clinical-and-serum-biomarkers-and-automated-quantitative-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/leveraging-tumor-organoids-to-model-drug-response-in-clear-cell-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/management-strategies-and-patient-outcomes-among-lpc-patients-with-persistently-positive-psa-after-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-geospatial-analysis-with-multiplex-immunofluorescence-to-analyze-tumor-immune-microenvironmen 2026-08-24 monthly 0.7 https://rjrindex.com/articles/spatial-analysis-of-the-immune-microenvironment-and-identification-of-phenotypes-of-prognostic-signi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1b2-study-evaluating-the-activity-of-tinengotinib-in-combination-with-androgen-receptor-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/initial-biopsy-results-of-the-patrol-study-prostate-screening-for-people-with-inherited-risk-of-dev 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-proto-oncogene-n-ras-transcript-level-and-overall-survival-in-node-negative-musc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-ii-clinical-study-of-camrelizumab-plus-apatinib-in-combination-with-stereotactic-body-radiot 2026-08-24 monthly 0.7 https://rjrindex.com/articles/application-of-ml-models-to-predict-postoperative-outcomes-in-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pparg-protein-expression-in-advanced-urothelial-carcinoma-and-selection-for-response-to-fx-909-a-fi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psma-pet-vs-pelvic-mri-in-biochemically-recurrent-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pathological-subclassification-of-t3-upper-tract-urothelial-carcinoma-complementary-evidence-for-ex 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frequency-and-impact-of-a-genome-wide-homologous-recombination-deficiency-signature-hrdsig-on-the-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-the-proficiency-of-chatgpt-4o-in-an-image-based-robot-assisted-radical-prostatectomy-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/avelumab-maintenance-in-patients-with-metastatic-urothelial-carcinoma-in-a-real-life-expanded-access 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-avelumab-first-line-1l-maintenance-therapy-and-subsequent-treatment-tx-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessment-of-pathologic-responses-from-unstructured-pathology-reports-using-large-language-models 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-of-nadofaragene-firadenovec-in-bcg-unresponsive-non-muscle-invasive-bladder-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-and-safety-results-from-rad-io-a-multi-stage-trial-of-durvalumab-medi4736-with-chemor 2026-08-24 monthly 0.7 https://rjrindex.com/articles/dna-damage-repair-alterations-as-predictive-biomarker-for-platinum-based-chemotherapy-in-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-results-from-the-phase-2-litespark-003-study-of-belzutifan-plus-cabozantinib-in-patients-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-kidney-injury-molecule-1-kim-1-in-association-with-kidney-injury-biomarkers-and-outcom 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-global-disparities-in-clinical-trial-availability-for-renal-cell-carcinoma-rcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/presurgical-treatment-for-inferior-vena-cava-tumor-thrombus-in-patients-with-renal-cell-carcinoma-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validation-of-new-prognostic-factors-for-relapse-in-patients-with-clinical-stage-i-seminoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-vascular-patterns-of-clear-cell-renal-cell-carcinoma-and-immune-cell-infiltratio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/application-of-canary-histology-classifier-in-prostate-biopsies-for-risk-stratification 2026-08-24 monthly 0.7 https://rjrindex.com/articles/computational-pathology-based-classifier-for-predicting-gleason-grade-group-upgrading-on-radical-pro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-preliminary-results-of-artificial-intelligence-generated-explainable-treatment-recommendation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/choice-of-androgen-receptor-pathway-inhibitors-arpi-by-disease-volume-and-timing-of-metastases-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-and-radiographic-trends-in-patients-with-renal-angiomyolipomas-aml 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-statin-use-with-overall-survival-and-cardiac-adverse-events-in-patients-with-advanced 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-trial-of-neoadjuvant-futibatinib-plus-durvalumab-for-cisplatin-ineligible-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patterns-of-hospital-admissions-and-readmissions-due-to-immune-related-adverse-events-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-clinical-tools-to-monitor-cardiovascular-cv-risk-in-men-with-localized-high-risk-or-loc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analysis-of-gut-microbiota-profiles-in-patients-with-prostate-cancer-the-promise-japan-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-oncopig-bladder-cancer-model-an-innovative-large-animal-platform-for-evaluating-treatment-effec 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-geographic-and-demographic-characteristics-on-treatment-with-lu-psma-for-metastatic-castra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-survival-benefits-of-adjuvant-immunotherapy-in-muscle-invasive-urothelial-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/correlates-of-immunotherapy-response-in-metastatic-clear-cell-renal-cell-carcinoma-from-circulating 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-23-study-of-bicycle-toxin-conjugate-zelenectide-pevedotin-bt8009-targeting-nectin-4-in-pa-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-natural-language-processing-algorithm-to-extract-mri-and-biopsy-related-phenotypes-for-prostate-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/etctn-10483-phase-ib-trial-of-erdafitinib-e-combined-with-enfortumab-vedotin-ev-following-plati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/disease-management-costs-and-healthcare-resource-utilization-by-progression-health-state-among-patie 2026-08-24 monthly 0.7 https://rjrindex.com/articles/final-overall-survival-os-with-talazoparib-tala-enzalutamide-enza-as-first-line-1l-treatme 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hydroxychloroquine-effects-on-tumor-suppressor-par-4-levels-in-patients-with-oligometastatic-prostat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metastasis-directed-radiotherapy-in-oligometastatic-bladder-and-upper-tract-cancer-a-single-institu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/complications-after-transurethral-resection-of-bladder-tumor-findings-from-the-2022-acs-nsqip-datab 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-estrogen-response-pathway-as-a-putative-predictive-biomarker-of-neoadjuvant-pembrolizumab-benefi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathological-variations-between-early-and-late-recurrence-in-bladder-cancer-post-radical-cyst 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chapter-platform-201-phase-2-trial-of-pimitespib-plus-enzalutamide-for-patients-with-metastatic-cas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prospective-observational-study-in-japanese-patients-with-metastatic-castration-sensitive-prostate-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/addition-of-darolutamide-to-first-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/determining-lung-cancer-screening-eligibility-in-a-surgically-treated-urothelial-carcinoma-populatio 2026-08-24 monthly 0.7 https://rjrindex.com/articles/analyses-on-impact-of-tumor-burden-at-progression-and-changes-in-imdc-from-baseline-in-patients-pts 2026-08-24 monthly 0.7 https://rjrindex.com/articles/trends-in-cardiovascular-mortality-in-older-adults-with-malignant-neoplasms-of-male-genital-organs-i 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-outcomes-for-radiographic-node-positive-prostate-cancer-following-definitive-radiotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-evaluation-of-stereotactic-body-radiation-therapy-sbrt-during-lutetium-177-psma-617-177lu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/finding-the-right-partner-triplet-therapy-for-first-line-advanced-biliary-tract-cancers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-highly-aggressive-ductal-prostate-tumours-with-poly-adp-ribose-polymerase-inhibitor-parpi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/organ-perforation-and-fistula-formation-as-adverse-events-in-patients-receiving-tyrosine-kinase-inhi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-apalutamide-in-metastatic-castration-sensitive-prostate-cancer-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gut-health-and-prostate-cancer-the-influence-of-a-specific-phytochemical-rich-food-capsule-plus-or 2026-08-24 monthly 0.7 https://rjrindex.com/articles/preliminary-results-from-legend-a-phase-2-study-of-detalimogene-voraplasmid-eg-70-a-novel-non-v 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-reported-outcome-pro-assessment-and-reporting-in-first-line-1l-locally-advanced-or-metas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/examining-community-social-vulnerability-domains-and-influence-on-treatment-selection-for-men-with-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/hospitalizations-in-veterans-treated-with-monotherapy-vs-combination-therapy-for-metastatic-hormone 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-the-impact-on-overall-survival-curves-of-patients-with-metastatic-castration-sensitive 2026-08-24 monthly 0.7 https://rjrindex.com/articles/comparison-of-digital-pathology-ai-models-genomics-classifier-and-clinical-variables-in-predicting 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-impact-of-neoadjuvant-therapy-on-the-formation-of-tertiary-lymphatic-structures-and-the-distinct 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-survival-prediction-model-for-veterans-with-advanced-bladder-cancer-bc-treated-with-immune-check 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-cell-expression-analysis-from-the-phase-2-trial-of-abiraterone-olaparib-or-abira 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-bleomycin-shortage-in-patients-with-advanced-testicular-non-seminoma-germ-cell-tumors-a-m 2026-08-24 monthly 0.7 https://rjrindex.com/articles/multimodal-management-of-oligometastatic-and-oligoprogressive-renal-cancer-patients-with-extra-lung 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effectiveness-and-safety-of-rc48-adc-in-combination-with-toripalimab-as-neoadjuvant-treatment-in-her 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-tumor-burden-or-focality-in-recurrent-low-grade-intermediate-risk-non-muscle-invasive-blad-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-evaluation-of-therapeutic-outcomes-of-percutaneous-usct-guided-bipolar-radiofrequency-ablation 2026-08-24 monthly 0.7 https://rjrindex.com/articles/neoadjuvant-darolutamide-and-relugolix-combination-preceding-radical-prostatectomy-for-high-risk-loc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ethnic-disparities-in-clinical-trials-for-fda-approved-drugs-in-renal-cell-carcinoma-an-analysis-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-alterations-in-intraductal-prostate-cancer-insights-from-the-genomic-umbrella-neoadjuvant-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mevrometostat-pf-06821497-an-enhancer-of-zeste-homolog-2-ezh2-inhibitor-in-combination-with-en 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-olaparib-ola-plus-abiraterone-abi-versus-placebo-pbo-plus-abi-in-patients-pts-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-12-trial-of-durvalumab-plus-intravesical-gemcitabine-and-docetaxel-in-bcg-unresponsive-non 2026-08-24 monthly 0.7 https://rjrindex.com/articles/systemic-therapy-for-stage-i-iii-anal-squamous-cell-carcinoma-asco-guideline 2026-08-24 monthly 0.7 https://rjrindex.com/articles/influence-of-mris-performed-in-a-6-week-interval-on-the-histopathological-detection-of-prostate-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/biomarker-testing-patterns-among-patients-newly-diagnosed-with-prostate-cancer-in-a-community-oncolo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/detection-of-mutations-in-homologous-recombination-repair-hrr-pathway-genes-using-liquid-biopsy-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinically-advanced-urothelial-bladder-cancer-caubc-in-young-onset-bladder-cancer-youc-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/whole-slide-multiplexed-tissue-imaging-of-prostate-adenocarcinoma-to-investigate-immune-niches-in-hi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patterns-of-split-dose-gemcitabine-and-cisplatin-gc-use-in-patients-with-locally-advanced-or-metas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/updated-results-of-the-tide-a-study-evaluating-avelumab-ave-plus-intermittent-axitinib-axi-in-pr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/long-follow-up-quality-of-life-outcomes-from-an-investigator-initiated-randomized-trial-of-enzalutam 2026-08-24 monthly 0.7 https://rjrindex.com/articles/incidence-of-embark-and-eau-high-risk-biochemical-recurrence-and-prostate-cancer-mortality-a-real-l 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-different-therapeutic-modalities-for-patients-with-metachronous-oligometastatic-renal-ce 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-non-coding-rna-based-classifier-for-favorable-outcomes-in-clinically-organ-confined-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/an-online-clustering-algorithm-predicting-model-for-prostate-cancer-based-on-phi-related-variables-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/innovative-diagnostic-approaches-serum-protein-markers-in-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/do-tissue-based-biomarkers-in-metastatic-clear-cell-renal-cell-carcinoma-perform-better-when-derived 2026-08-24 monthly 0.7 https://rjrindex.com/articles/jccg-all-b12-evaluation-of-intensified-therapies-with-vincristinedexamethasone-pulses-and-asparagi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/estimation-of-overall-survival-in-immunotherapy-treated-bladder-cancer-using-computer-vision 2026-08-24 monthly 0.7 https://rjrindex.com/articles/non-clear-cell-renal-cell-carcinoma-in-the-immune-checkpoint-era-a-retrospective-study-on-survival 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-afu-getug-20-a-randomised-phase-3-trial-of-adjuvant-androgen-deprivation-therapy-with-le 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predictive-value-of-neoadjuvant-therapy-combined-with-vi-rads-re-scoring-in-bladder-preservation-for 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transdermal-oestradiol-te2-patches-as-androgen-deprivation-therapy-adt-efficacy-and-safety-of-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/concurrent-pembrozulimab-and-radiation-treatments-in-the-management-of-locally-advanced-bladder-canc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/time-from-medication-order-to-administration-of-cabazitaxel-c-vs-lutetium-lu-177-vipivotide-tetra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/interpath-004-a-phase-2-randomized-double-blind-study-of-adjuvant-pembrolizumab-pembro-with-v94 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mortality-risk-in-clinical-t1a-renal-cell-carcinoma-rcc-with-synchronous-metastasis-sm-a-compar 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ethnic-disparities-in-clinical-trials-for-fda-approved-drugs-in-urothelial-cancer-an-analysis-in-th 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-12-omaha-01a-substudy-of-oral-cyp11a1-inhibitor-opevesostat-alone-or-in-combination-with-othe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psa-based-intermediate-endpoints-to-compare-radiotherapy-and-radical-prostatectomy-for-the-treatment 2026-08-24 monthly 0.7 https://rjrindex.com/articles/five-year-changes-in-urinary-function-and-prostate-volume-in-patients-with-localized-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-association-between-bone-pain-and-radiologic-progression-free-survival-rpfs-in-pati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-sequence-ts-and-overall-survival-os-in-patients-with-metastatic-urothelial-cancer-muc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lutetium-177-psma-radioligand-therapy-in-taxan-naive-first-and-second-line-metastatic-castration-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/baseline-fracture-risk-for-prostate-cancer-patients-initiating-long-term-androgen-deprivation-therap 2026-08-24 monthly 0.7 https://rjrindex.com/articles/pilot-study-evaluating-duplex-sequencing-of-urinary-dna-as-a-biomarker-for-recurrence-in-non-muscle 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-characteristics-of-patients-with-metastatic-hormone-sensitive-prostate-cancer-treated-with-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patterns-of-next-generation-sequencing-and-associated-next-line-systemic-therapy-use-in-metastatic-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/influence-of-gut-microbiome-composition-on-treatment-efficacy-and-toxicity-in-bladder-cancer-a-comp 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-spectrum-of-disease-within-gleason-grade-group-3-results-from-a-large-institutional 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ctdna-characterization-in-mcrpc-patients-with-pathogenic-germline-variants 2026-08-24 monthly 0.7 https://rjrindex.com/articles/germline-correlates-of-clinical-outcomes-in-aggressive-prostate-cancer-subtypes-treated-with-radiati 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-clinical-and-pathologic-predictors-for-pathologic-lymph-node-positivity-pn-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/rates-of-acute-gi-and-gu-toxicities-with-dose-escalated-intensity-modulated-proton-therapy-impt-fo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prostate-cancer-real-world-evidence-registry-procare-recurrent-and-metastatic-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-psa-nadir-on-long-term-survival-in-metastatic-hormone-sensitive-prostate-cancer-final-10 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-impact-of-micropapillary-histology-and-clinical-staging-on-overall-survival-in-bladder-cancer-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/vasculo-immune-modulatory-effects-of-anti-vegf-therapy-in-metastatic-clear-cell-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/converge-01-dosimetry-randomized-dose-optimization-dose-escalation-and-efficacy-of-ac-225-rosopa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/osteonecrosis-of-the-jaw-onj-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-role-of-circulating-kidney-injury-molecule-1-kim-1-in-metastatic-renal-cell-carcinoma-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/using-ai-to-identify-optimal-clinical-genomic-and-radiographic-prognostic-features-and-novel-risk 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psma-positive-tumor-vessels-around-renal-cell-carcinoma-with-high-angiogenic-potential-as-therapeuti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-evidence-for-factors-associated-with-development-of-castration-resistant-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/carboplatin-in-patients-with-metastatic-castration-resistant-prostate-cancer-harboring-somatic-or-ge-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/abca1-and-abcg1-cholesterol-transporters-expression-on-metastatic-renal-cell-carcinoma-impact-on-im 2026-08-24 monthly 0.7 https://rjrindex.com/articles/burden-of-cancer-in-metastatic-renal-cell-carcinoma-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-and-ethnic-disparities-in-urinary-continence-recovery-post-prostatectomy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cabozantinib-as-subsequent-therapy-to-an-immune-checkpoint-based-therapy-in-renal-cell-carcinoma-ph 2026-08-24 monthly 0.7 https://rjrindex.com/articles/changes-in-circulating-tumor-cells-ctcs-and-her2-expression-in-evaluating-the-efficacy-of-neoadjuv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psa-response-and-survival-based-on-metastatic-site-in-patients-with-metastatic-castration-resistant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-localized-high-risk-prostate-cancer-pc-and-an-androgen-receptor-low-subpopulation-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-concomitant-medication-use-on-treatment-outcomes-in-patients-with-rcc-treated-with-immune 2026-08-24 monthly 0.7 https://rjrindex.com/articles/overall-survival-and-quality-of-life-with-sup177sup-lu-lu-psma-617-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/optimizing-treatment-approaches-in-nested-bladder-tumors-a-multicenter-retrospective-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-immune-checkpoint-inhibitor-rechallenge-in-urothelial-carcinoma-results-from-a-global-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/validation-of-navigator-assisted-hypofractionation-navah-program-surveys-in-african-american-prost 2026-08-24 monthly 0.7 https://rjrindex.com/articles/feasibility-of-surgical-orchiectomy-in-prostate-cancer-patients-on-long-term-luteinizing-hormone-rel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psa-response-to-lu177-psma-617-in-patients-experiencing-xerostomia-and-ocular-dryness-in-metastatic 2026-08-24 monthly 0.7 https://rjrindex.com/articles/patient-satisfaction-with-geriatric-and-functional-assessments-and-referral-to-frailty-related-inter 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-outcomes-of-first-line-dual-immunotherapy-versus-combination-vegf-immunotherapy-in-interm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/extensive-necrosis-as-a-prognostic-indicator-in-metastatic-rcc-patients-undergoing-deferred-cytoredu 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prostate-cancer-risk-groups-by-psma-pet-promise-ppp-results-from-an-international-multi-center-re 2026-08-24 monthly 0.7 https://rjrindex.com/articles/germline-dna-repair-gene-variants-in-patients-under-active-surveillance-for-low-grade-bladder-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multi-centre-review-of-the-use-of-adjuvant-pembrolizumab-for-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/muscle-invasive-bladder-cancer-treatment-selection-in-an-emerging-treatment-era-a-patient-preferenc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/erratum-pembrolizumab-or-placebo-plus-adjuvant-chemotherapy-with-or-without-radiotherapy-for-newly 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-alterations-and-their-pathologic-responses-in-high-risk-localized-prostate-cancer-hrlpc-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/epic-b-phase-ii-trial-of-cemiplimab-as-first-line-treatment-in-advanced-penile-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinical-characteristics-and-treatment-patterns-of-patients-with-muscle-invasive-bladder-cancer-a-r 2026-08-24 monthly 0.7 https://rjrindex.com/articles/targeting-trop2-in-aggressive-variant-and-neuroendocrine-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-circulating-kidney-injury-marker-1-kim-1-as-a-prognostic-and-predictive-biomarker-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/swog-s1815-a-phase-iii-randomized-trial-of-gemcitabine-cisplatin-and-nab-paclitaxel-versus-gemcit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/checkpoint-blockade-as-neoadjuvant-strategy-a-single-arm-meta-analysis-of-dual-pd-1pd-l1-and-ctla 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-and-clinical-outcomes-of-androgen-receptor-inhibitors-aris-for-non-metastatic-castration-resis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-of-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc-rec-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/ethnic-disparities-in-clinical-trials-for-fda-approved-drugs-in-prostate-cancer-a-post-covid-19-era 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cross-resistance-among-novel-androgen-receptor-axis-targeted-agents-in-non-metastatic-castration-res 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ii-trial-of-image-guided-oligometastatectomy-and-radiation-therapy-in-recurrent-prostate-cance 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sarcopenia-as-a-marker-to-assess-the-surveillance-necessity-after-a-5-year-cancer-free-period-in-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-1b2-study-of-combination-sup177sup-lu-girentuximab-plus-cabozant 2026-08-24 monthly 0.7 https://rjrindex.com/articles/does-treatment-tx-for-mental-health-illness-mhi-impact-prostate-cancer-pc-tx-and-outcomes 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genomic-features-of-prostate-cancer-patients-with-and-without-ductal-adenocarcinoma-da-based-on-li 2026-08-24 monthly 0.7 https://rjrindex.com/articles/gene-expression-signatures-in-biopsy-cores-as-predictors-of-coexisting-higher-grade-disease-in-gleas 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-from-the-prior-treatment-cohort-of-a-phase-iii-study-of-nivolumab-and-axitinib-in-patients 2026-08-24 monthly 0.7 https://rjrindex.com/articles/assessing-genomic-instability-gi-by-shallow-whole-genome-sequencing-swgs-to-predict-parp-inhibit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-sabr-with-tki-and-io-therapy-in-patients-with-mrcc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prognostic-significance-of-psa-in-the-outcomes-of-patients-with-high-risk-localized-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1b-study-of-cabozantinib-and-nivolumab-with-abiraterone-cabios-in-metastatic-castration-se 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-optimizing-deephrd-interpretability-for-enhanced-clinical-decision-making 2026-08-24 monthly 0.7 https://rjrindex.com/articles/peak-corticosteroid-dose-for-immune-related-adverse-events-and-survival-not-the-whole-story 2026-08-24 monthly 0.7 https://rjrindex.com/articles/clinicopathological-characteristics-of-cancer-of-unknown-primary-cup-with-renal-profile-using-gene 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reply-to-peak-corticosteroid-dose-for-immune-related-adverse-events-and-survival-not-the-whole-sto 2026-08-24 monthly 0.7 https://rjrindex.com/articles/belzutifan-monotherapy-in-chinese-patients-pts-with-von-hippel-lindau-vhl-disease-associated-tum 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-cabold-study-a-real-life-prospective-cohort-evaluating-the-combination-of-cabozantinib-and-nivo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-of-high-risk-prostate-specific-antigen-level-during-active-surveillance-with-targeted-and-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/late-onset-of-apalutamide-related-skin-toxicity-in-black-men-with-advanced-prostate-cancer-a-divers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/exploring-the-efficacy-of-belzutifan-in-the-treatment-of-renal-cell-carcinoma-associated-with-von-hi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-the-2012-and-2018-uspstf-statements-on-prostate-cancer-screening-and-metastatic-rates-in-k 2026-08-24 monthly 0.7 https://rjrindex.com/articles/results-of-a-cross-sectional-survey-to-explore-determinants-of-health-promoting-activities-among-his 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-nanosomal-docetaxel-lipid-suspension-in-indian-patients-with-metastatic-castr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/androgen-receptor-alterations-and-survival-in-veterans-who-develop-metastatic-castrate-resistant-pro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/local-definitive-therapy-ldt-utilization-patterns-and-outcomes-in-chromophobe-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/paclitaxel-ifosfamide-cisplatin-tip-in-patients-with-advanced-urethral-adenocarcinoma-a-single 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-line-therapies-analysis-in-advancedmetastatic-urothelial-carcinoma-prognostic-insights-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/final-oncological-outcomes-of-the-randomized-phase-ii-trial-arneo-neoadjuvant-degarelix-with-or-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/androgen-suppression-with-abiraterone-acetate-leuprolide-parp-inhibition-and-stereotactic-body-ra 2026-08-24 monthly 0.7 https://rjrindex.com/articles/molecular-evolution-of-hrr-gene-alterations-in-metastatic-prostate-cancer-a-ctdna-based-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-deferred-cytoreductive-nephrectomy-in-the-era-of-the-immunotherapy-in-metastatic-renal-cel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/role-of-circulating-tumor-dna-ctdna-in-locally-advanced-la-and-metastatic-urothelial-cancer-muc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/epigenomic-profiling-of-circulating-chromatin-for-early-detection-and-monitoring-of-neuroendocrine-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/intravesical-gemcitabine-and-docetaxel-combined-with-intravenous-tislelizumab-as-a-durable-strategy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/determining-an-immunohistochemical-profile-to-predict-response-to-intravesical-bacillus-calmette-gue 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prospective-trial-of-a-structured-exercise-program-to-lessen-fatigue-in-patients-with-advanced-pro 2026-08-24 monthly 0.7 https://rjrindex.com/articles/implementation-and-preliminary-validity-of-the-functional-assessment-of-cancer-therapy-radionuclid 2026-08-24 monthly 0.7 https://rjrindex.com/articles/the-prognostic-significance-of-circulating-tumor-dna-in-prostate-cancer-a-systematic-review-and-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-post-orchiectomy-systemic-inflammatory-indexes-and-tumor-characteristics-in-clin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/darolutamide-plus-androgen-deprivation-therapy-adt-in-patients-with-high-risk-biochemical-recurren-1 2026-08-24 monthly 0.7 https://rjrindex.com/articles/natural-history-and-risk-stratification-of-biochemical-recurrence-in-prostate-cancer-treated-with-de 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psma-based-pet-imaging-in-newly-diagnosed-high-risk-localized-prostate-cancer-a-national-cancer-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/functional-and-oncological-outcome-of-primary-nerve-sparing-retroperitoneal-lymph-node-dissection-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/emetpro-a-multicenter-international-retrospective-analysis-evaluating-patients-pts-with-metasta 2026-08-24 monthly 0.7 https://rjrindex.com/articles/frailty-and-adverse-clinical-outcomes-in-prostate-cancer-patients-an-analysis-from-the-radical-pc-c 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-of-neoadjuvant-parp-inhibition-followed-by-radical-prostatectomy-rp-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-efficacy-of-cabozantinib-in-patients-with-advanced-renal-cell-carcinoma-with-bone-met 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metastatic-renal-cell-carcinoma-mrcc-primary-refractory-patients-to-first-line-io-tki-and-io-io-co 2026-08-24 monthly 0.7 https://rjrindex.com/articles/effects-of-emerin-dysregulation-on-the-very-small-nuclear-phenotype-and-neuronal-differentiation-and 2026-08-24 monthly 0.7 https://rjrindex.com/articles/prevention-diagnosis-and-management-of-penile-cancer-in-the-lgbtq-community-a-systematic-review 2026-08-24 monthly 0.7 https://rjrindex.com/articles/portos-gene-signature-as-a-predictor-of-risk-of-adverse-events-after-dose-escalated-vs-lower-dose-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/radical-prostatectomy-rp-versus-radiotherapy-rt-in-high-risk-prostate-cancer-hr-pca-emulated 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-2-study-of-perioperative-lenvatinib-l-with-pembrolizumab-p-in-patients-with-locally-advanc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/atezolizumab-plus-chemotherapy-with-or-without-bevacizumab-in-advanced-biliary-tract-cancer-clinica 2026-08-24 monthly 0.7 https://rjrindex.com/articles/closing-the-gap-evaluating-medicares-low-income-subsidy-support-for-optimal-cancer-care 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-patterns-and-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer-in-the-b 2026-08-24 monthly 0.7 https://rjrindex.com/articles/extracellular-dna-in-patients-with-urothelial-carcinoma-of-the-bladder 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-comparison-of-time-to-next-treatment-ttnt-time-to-castration-resistance-ttcr-and-ov 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-targeted-therapies-tt-after-hif-2-inhibitor-based-treatment-in-advanced-renal-cell-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/global-phase-3-open-label-single-arm-studies-to-evaluate-the-efficacy-safety-and-pharmacokineti 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-lenvatinib-plus-everolimus-in-metastatic-renal-cell-carcinoma-after-immune-ch 2026-08-24 monthly 0.7 https://rjrindex.com/articles/in-field-progression-following-radiation-therapy-as-a-prognostic-biomarker-for-lutetium-177-psma-617 2026-08-24 monthly 0.7 https://rjrindex.com/articles/bipolar-androgen-therapy-bat-for-nonmetastatic-castration-resistant-prostate-nmcrpc-cancer-progr 2026-08-24 monthly 0.7 https://rjrindex.com/articles/image-based-artificial-intelligence-algorithms-for-molecular-diagnostics-in-prostate-pathology-how 2026-08-24 monthly 0.7 https://rjrindex.com/articles/imtapi-loss-in-primary-kidney-tumors-a-comprehensive-genomic-profiling-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-and-efficacy-of-neoadjuvant-immunotherapy-with-durvalumab-medi-4736-in-combination-with-neo 2026-08-24 monthly 0.7 https://rjrindex.com/articles/treatment-tolerability-and-outcomes-of-enfortumab-vedotin-plus-pembrolizumab-in-advanced-urothelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-based-on-line-of-therapy-and-treatment-trends-with-cabazitaxel-in-patients-pts-w 2026-08-24 monthly 0.7 https://rjrindex.com/articles/discordance-in-her2-expression-in-primary-and-recurrentmetastatic-lesions-of-upper-tract-urothelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-multi-center-phase-ibii-study-of-rc48-adc-combined-with-tislelizumab-as-neoadjuvant-treatment-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/global-spatiotemporal-trends-in-prostate-cancer-burden-and-its-socioeconomic-disparities-an-observa 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-liquid-biopsies-on-early-detection-monitoring-and-prognostication-in-prostate-cancer-a 2026-08-24 monthly 0.7 https://rjrindex.com/articles/extreme-bipolar-androgen-therapy-alternating-darolutamide-and-testosterone-cypionate-in-patients-wi 2026-08-24 monthly 0.7 https://rjrindex.com/articles/second-primary-malignancy-in-bladder-cancer-a-retrospective-population-based-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/national-cancer-system-characteristics-and-prostate-cancer-outcomes-a-global-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-organoid-based-drug-sensitivity-screening-to-guide-the-treatment-of-mcrpc-pat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/characterization-of-circulating-tumor-dna-ctdna-burden-and-its-association-with-real-world-overall 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluation-of-ctdna-alterations-in-lethal-mcrpc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/use-of-integrated-multi-omics-analysis-to-analyze-prognostic-molecular-subtype-in-collecting-duct-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/homologous-recombination-repair-mutation-testing-patterns-in-metastatic-castration-resistant-prostat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/stage-ii-embryonal-predominant-nsgct-minimizing-treatment-burden 2026-08-24 monthly 0.7 https://rjrindex.com/articles/management-of-relapsed-stage-i-seminomatous-germ-cell-tumor-with-retroperitoneal-or-pelvic-only-rela 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-detection-of-recurrent-prostate-cancer-using-18f-dcfpyl-petct-petct-in-patients-with-minimal 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-2-study-of-cabozantinib-in-combination-with-atezolizumab-as-neoadjuvant-treatment-for-muscle 2026-08-24 monthly 0.7 https://rjrindex.com/articles/population-adjusted-network-meta-analyses-nma-to-evaluate-the-efficacy-of-treatment-alternatives-f 2026-08-24 monthly 0.7 https://rjrindex.com/articles/sociodemographic-predictors-of-the-late-stage-diagnosis-in-patients-with-prostate-cancer-a-retrospe 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cancer-control-outcomes-of-metastatic-castration-resistant-prostate-cancer-patients-with 2026-08-24 monthly 0.7 https://rjrindex.com/articles/early-findings-from-a-national-quality-improvement-qi-program-to-address-disparities-in-bladder-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/psa-dynamics-enhancing-predictive-models-in-prostate-cancer-follow-up 2026-08-24 monthly 0.7 https://rjrindex.com/articles/chromosomal-instability-in-tumor-suppressor-genes-altered-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/impact-of-adjuvant-intraarterial-chemotherapy-on-survival-for-patients-with-stage-iiia-iiib-bladder 2026-08-24 monthly 0.7 https://rjrindex.com/articles/reduction-of-systemic-chemotherapy-by-primary-retroperitoneal-lymph-node-dissection-in-low-volume-me 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-comparison-of-cabazitaxel-vs-177-lutetium-psma-radioligand-therapy-in-metastatic-castrat 2026-08-24 monthly 0.7 https://rjrindex.com/articles/racial-disparities-in-incidence-based-mortality-and-survival-outcomes-in-testicular-cancer-in-adoles 2026-08-24 monthly 0.7 https://rjrindex.com/articles/management-of-relapsed-primary-retroperitoneal-rp-germ-cell-tumor-gct-after-front-line-chemother 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-clinical-trial-evaluating-the-efficacy-and-safety-of-disitamab-vedotin-plus-tislelizumab-combined 2026-08-24 monthly 0.7 https://rjrindex.com/articles/predicting-long-term-outcomes-following-radical-prostatectomy-using-a-validated-pathology-based-mult 2026-08-24 monthly 0.7 https://rjrindex.com/articles/outcomes-with-first-line-ipilimumab-and-nivolumab-for-patients-with-metastatic-renal-cell-carcinoma 2026-08-24 monthly 0.7 https://rjrindex.com/articles/metabolic-determinants-of-exceptional-response-to-immune-checkpoint-inhibition-in-renal-cell-carcino 2026-08-24 monthly 0.7 https://rjrindex.com/articles/core-008-a-phase-2-multi-arm-multi-cohort-open-label-study-to-evaluate-intravesical-cretostimoge 2026-08-24 monthly 0.7 https://rjrindex.com/articles/large-language-models-llms-for-inferring-genomic-characteristics-and-facilitating-genomic-literacy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-cell-rna-biomarker-for-bavdegalutamide-arv-110-in-metastatic-castration-resistan 2026-08-24 monthly 0.7 https://rjrindex.com/articles/phase-ibii-clinical-trial-of-oncolytic-virus-intravesical-irrigation-for-preventing-recurrence-afte 2026-08-24 monthly 0.7 https://rjrindex.com/articles/safety-profile-of-lutetium-177-in-patients-with-impaired-renal-function-a-retrospective-analysis-of 2026-08-24 monthly 0.7 https://rjrindex.com/articles/mature-phase-1-follow-up-of-alpha-emitter-225ac-j591-with-177lu-psma-iampt-in-advanced-prostate-ca 2026-08-24 monthly 0.7 https://rjrindex.com/articles/glp-1-analogues-and-prostate-cancer-incidence-a-systematic-review-and-meta-analysis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/cabozantinib-cabo-and-nivolumab-nivo-with-or-without-cbm588-in-patients-with-metastatic-renal-ce 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-rates-of-surgical-overtreatment-of-prostate-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-sup177sup-lu-psma-617-with-or-without-arpis 2026-08-24 monthly 0.7 https://rjrindex.com/articles/transcriptional-profiling-of-patients-with-metastatic-hormone-sensitive-prostate-cancer-to-uncover-s 2026-08-24 monthly 0.7 https://rjrindex.com/articles/survival-outcomes-among-metastatic-castration-resistant-prostate-cancer-patients-treated-with-androg 2026-08-24 monthly 0.7 https://rjrindex.com/articles/interpretable-machine-learning-for-prostate-biopsy-cohort-study 2026-08-24 monthly 0.7 https://rjrindex.com/articles/systemic-therapy-clinical-trial-participation-in-patients-with-bladder-and-kidney-cancers 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-prospective-single-center-single-arm-clinical-study-of-adjuvant-toripalimab-combined-with-axitin 2026-08-24 monthly 0.7 https://rjrindex.com/articles/genome-scale-metabolic-reconstruction-of-urinary-microbiome-pathway-for-personalized-medicine 2026-08-24 monthly 0.7 https://rjrindex.com/articles/investigating-clinical-associations-between-genomic-alterations-and-prostate-cancer-lineage-states-u 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-comprehensive-evaluation-of-gene-expression-based-signatures-for-detecting-tertiary-lymphoid-struc 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-retrospective-real-world-study-of-disitamab-vedotin-combined-with-tislelizumab-versus-chemotherapy 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-between-abnormal-imdc-laboratory-criteria-after-surgery-and-cancer-specific-and-overall 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-and-safety-of-car-t-cell-therapy-in-penile-and-urethral-carcinomas-a-meta-analysis-of-prel 2026-08-24 monthly 0.7 https://rjrindex.com/articles/systemic-therapies-in-renal-cell-carcinoma-with-brain-metastases-a-comparative-meta-analysis-of-imm 2026-08-24 monthly 0.7 https://rjrindex.com/articles/a-phase-1b-open-label-multicenter-study-of-xaluritamig-in-patients-with-newly-diagnosed-localized 2026-08-24 monthly 0.7 https://rjrindex.com/articles/radonc-gpt-gpt-4o-versus-human-data-extraction-for-prostate-cancer-clinical-research 2026-08-24 monthly 0.7 https://rjrindex.com/articles/association-of-a-novel-ai-based-digital-pathology-chai-biomarker-with-progression-free-survival-p 2026-08-24 monthly 0.7 https://rjrindex.com/articles/current-impact-of-ureteral-carcinoma-amongst-racial-minorities-analysis-of-the-national-cancer-data 2026-08-24 monthly 0.7 https://rjrindex.com/articles/real-world-safety-of-first-line-1l-therapies-for-locally-advanced-or-metastatic-urothelial-cancer 2026-08-24 monthly 0.7 https://rjrindex.com/articles/circulating-tumor-dna-levels-and-related-kinetics-as-prognostic-biomarkers-for-clinical-outcomes-in 2026-08-24 monthly 0.7 https://rjrindex.com/articles/lewis-y-antigen-as-a-novel-target-for-car-chimeric-antigen-receptor-t-cell-therapy-in-patients-wit 2026-08-24 monthly 0.7 https://rjrindex.com/articles/evaluating-the-combined-role-of-hhla2-and-pd-l1-as-biomarkers-in-first-line-nivolumab-therapy-in-adv 2026-08-24 monthly 0.7 https://rjrindex.com/articles/first-in-human-phase-0-safety-imaging-pharmacokinetics-and-dosimetry-study-of-sup64 2026-08-24 monthly 0.7 https://rjrindex.com/articles/efficacy-of-nivolumab-plus-ipilimumab-in-t1an0m0-renal-cell-carcinoma-rcc-patients-results-from-3 2026-08-24 monthly 0.7 https://rjrindex.com/articles/deciphering-immune-genomic-markers-of-hyperprogression-in-patients-pts-with-metastatic-urothelial 2026-08-24 monthly 0.7 https://rjrindex.com/articles/severity-of-bleomycin-induced-lung-toxicity-in-indian-patients-with-intermediate-and-poor-risk-non-s 2026-08-24 monthly 0.7